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SEMAPHORIN 3F AS A NOVEL THERAPEUTIC  IN THE FIGHT 







 Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive form of 
cancer with a high mortality rate, primarily due to lack of effective treatment 
options. Current therapeutic approaches are limited to surgical resection of the 
pancreas during early stages of the disease and to the use of non-specific 
chemotherapeutic drugs such as gemcitabine, neither of which has successfully 
improved the 5-year survival rate of PDAC. Both the lack of effective treatments 
and the high mortality of the disease call for the urgent need to develop new 
therapeutic options.  
 
Objectives  
This thesis project focuses on an endogenous inhibitor of the neuropilin 2 
receptor (NRP2) called semaphorin 3F (SEMA3F) and its use as a potential new 
drug in the fight against pancreatic cancer. By binding the transmembrane 
receptor neuropilin 2 (NRP2), SEMA3F can inhibit angiogenesis and cellular 
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proliferation. Interestingly, given its role as a guidance molecule, it is also a 
potent mediator of cellular repulsion. All three of these effects will be analyzed in 
the context of this study.  
 
Methods  
 Syngeneic pancreatic cancer cells were injected orthotopically in two 
separate groups of mice. One group involved the use of transgenic Nrp2-/- mice, 
and served as a way to analyze the absence of the receptor on the vasculature 
and how that affects the growth of the primary tumor and the formation of 
metastases in the liver. The other group received intravenous injections of 
SEMA3F-expressing and control adenovirus, and served to explore the effect of 
SEMA3F as a potential therapy against the growth of the primary tumor in the 
pancreas and distant metastases in the liver.   
 
Results 
 We observed a decrease in pancreatic tumor and metastatic growth in the 
absence of Nrp2 in our transgenic mouse model compared to the WT control. 
Mice injected with SEMA3F-expressing adenovirus also showed a decrease in 
primary tumor growth as well as a reduction in the formation of metastases in the 








 Nrp2 mediates angiogenesis in pancreatic cancer, which facilitates the 
growth of the primary tumor as well as the formation of metastases. Our results 
indicate that the anti-angiogenic, anti-proliferative and repulsive actions of 
SEMA3F could be used to develop an effective treatment option for pancreatic 
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The goal of this thesis project is to analyze the role of a transmembrane  
receptor called neuropilin 2 on pancreatic cancer cells and other cells within the 
tumor microenvironment. The experiments performed in this study were aimed at 
analyzing the role of neuropilin 2 as a mediator of primary tumor growth and 
metastases formation, as well as finding a potential anti-cancer therapy by 
targeting it with an endogenous inhibitor. This introduction section provides 
background information on the various topics that are relevant to this project and 





A functional vasculature is essential to ensure the adequate delivery of 
nutrients and oxygen to living and growing tissues. Unsurprisingly, the 
vasculature is one of the first systems to develop in embryogenesis (Adams and 
Eichmann 2010).The formation of a functional circulatory network during 
embryonic development is referred to as vasculogenesis, a process that relies on 
the migration and differentiation of endothelial precursor cells called angioblasts.  
Angioblasts move towards the center of the trunk to form the intermediate cell 
mass (Gering et al. 1998). Here, they form a primitive vascular plexus that 
undergoes a series of structural and morphological changes that lead to the 
formation of a functional vascular system, which is lined by endothelial cells (EC). 
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The spontaneous accumulation of EC at the intermediate cell mass 
(vasculogenesis) eventually results in the formation of the cardinal vein and the 
aorta, the first vein and first artery, respectively. Arterio-venous differentiation 
occurs before the formation of the heart and is guided by the differential 
expression of specific genes. 
The first genes to have been identified that are involved in vasculogenesis 
are receptor tyrosine kinases called Eph receptors and their ligands, ephrins 
(Hirai et al. 1987). Upon binding to ephrins, Eph receptors can mediate changes 
in the cytoskeletal dynamics of a cell, resulting in either attraction, repulsion or 
migration (Poliakov et al. 2008).  Given their ability to coordinate cellular 
interactions, ephrins are important mediator of morphogenesis during embryonic 
development. Interestingly, Eph/ephrin interactions are involved in the guidance 
of axons and the formation of synapses in the developing nervous system, much 
like semaphorin proteins, which will be discussed in great detail below (Villar-
Cerviño et al. 2013). 
In zebrafish it has been shown that the expression of EphB4 expressing, 
venous-fated endothelial precursor cells are repelled from ephrin B2-expressing, 
arterial-fated endothelial precursor cells and are therefore very likely to be 
implicated in the formation of the cardinal vein and the dorsal aorta (Herbert et al. 
2009). On embryonic day 9, the proepicardial layer of the developing heart, 
connects to the developing vascular plexus (Poelman et al. 2002).  
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The initiation of blood flow induces the expression of genes that 
orchestrate the remodeling of primitive vessels in order to induce the formation of 
a unidirectional, hierarchically organized vascular network. The morphological 
differences between veins and arteries are representative of the hemodynamic 
load that they have to carry. Indeed, as a general rule, arteries are surrounded by 
layers of smooth muscle and a specialized matrix, which allows them to 
withstand high pressures. Veins, on the other hand, are thinner and often lack 
the extensive muscular layers of arteries, which makes them more compliant and 
in turn renders them more suitable for storage of large blood volumes at lower 
pressures (Gaengel et al. 2009).    
Angiogenesis is different from vasculogenesis, in the sense that it 
describes the sprouting of new vessels from pre-existing ones. Endothelial cells 
are mostly quiescent during adulthood and proliferate primarily to allow the 
growth of certain tissues, such as wound healing, pregnancy or menstruation 
(Kerr et al. 2016). As a tissue grows, the proliferating cells progressively distance 
themselves from the vasculature, until they exceed the diffusion limit of oxygen 
which is about 100 to 200 um (Lovett et al. 2009). At this point, the onset of 
hypoxia causes the release of hypoxia-inducible transcription factors, which 
initiate the release of multiple growth factors (Krock et al. 2011). The latter 
orchestrate the complex mechanism of sprouting angiogenesis, a tightly 
regulated and sequential process consisting of very specific events.  
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The first step in sprout formation is the degradation of the basement 
membrane and the detachment of mural cells that wrap around the endothelial 
cells (Hinsbergh and Koolwijk 2008). Matrix metalloproteases contribute to the 
degradation of the surrounding matrix and promote the release of proangiogenic 
factors (Bergers et al. 2000). The detachment of mural cells on the other hand is 
mediated by angiopoietin-2 (Thurston et al. 2000). 
Next, tip cells, which as their name implies are located at the tip of the 
sprout, as well as stalk cells, which make up the rest of the newly formed sprout, 
are selected through complex signaling pathways (Gerhardt et al. 2003). 
Gradients of various pro-angiogenic growth factors guide the the tip cell into an 
area of the tissue that requires additional perfusion. Interestingly, tip cell 
proliferation shares some of the features of neuronal patterning and the guidance 
mechanism of both processes relies on the use of similar molecules (Adams and 
Eichmann 2010). 
The next step revolves around tube and branch formation, functions that 
are carried out primarily by the stalk cells. Fusion of the filopodia that project 
stalk cells allows them to coalesce and form a tubular structure with a lumen 
(Tung, et al. 2012). Following the formation of a tube with a lumen, two tip cells 
from two separate sprouts need to come in contact and undergo anastomosis 
(Fantin et al. 2010). Finally, the newly formed vascular loop undergoes a 
maturation process revolving around the recruitment of mural cells and pericytes 
(D’Amore et al. 1996). 
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In summary, the process of angiogenesis is a tightly regulated event that 
results in the formation of new vascular sprouts from pre-existing blood vessels. 
Each organ has specific microvessel densities that satisfy the tissues within it. In 
adults, endothelial cells are mostly quiescent and only proliferate during certain 
events during which the adequate perfusion of a tissue needs to be maintained, 
such as wound healing, menstruation and pregnancy. The deregulation of 
angiogenesis in pathology is highly problematic and will be discussed in further 
detail below.   
 
Angiogenesis: Pathology 
As previously discussed, angiogenesis is a tightly regulated physiological 
process that promotes the formation of new blood vessels from preexisting ones, 
usually in order to ensure the adequate perfusion of a growing tissue. Another 
form of tissue growth is cancer, which is defined by the uncontrolled proliferation 
of cells. In the early 1960’s, Dr. Judah Folkman, who is widely recognized as the 
founder of the field of angiogenesis research, recognized that tumors were well 
perfused with blood vessels, which had sprouted from the healthy surrounding 
tissue into the growing neoplastic mass. He recognized that in-vitro tumors were 
incapable of growing beyond a size of 2mm in diameter if they did not receive 
adequate blood supply from vessels (Folkman et al. 1963). However, upon 
implanting these tumors into mice, they quickly became vascularized and grew to  
sizes that exceeded 1cm3.  
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The decades of research that followed this discovery revealed that there a 
several major differences between pathologically and physiologically regulated 
angiogenesis, the most striking one being the morphological and structural 
abnormalities of unhealthy vessels (Nagy et al. 2009). The precise molecular 
gradients that normally guide the sprout in a very specific direction are replaced 
by the chaotic release of large quantities of pro-angiogenic molecules, primarily 
the vascular endothelial growth factor A (VEGF-A). 
For example, malignant tumorigenesis is often accompanied by 
inflammation and hence the uncontrolled release of potent molecules that 
promote blood vessel proliferation (Schoppmann et al. 2002). As a consequence, 
tumor vessels are tortuous and crooked, often disrupting or even obstructing 
blood flow. The resulting deficit in tissue perfusion often causes tumors to contain 
large areas of necrotic tissue, which is correlated with a poor prognosis in certain 
types of cancer (Edwards et al. 2003). 
The continuous release of angiogenic stimulators from the tumor also 
induces a number of structural issues, such as the constant breakdown of the 
basement membrane (Baluk et al. 2003). As previously discussed, the 
degradation of the basement membrane is essential to allow the formation of a 
sprout during physiological angiogenesis. But the persistent remodeling of the 
basement membrane in cancer severely undermines the structural integrity of 
blood vessels.  
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Furthermore, the contact between pericytes and endothelial cells, which 
under physiological conditions promotes stability in healthy tissues, is absent in 
tumor vessels (Abramsson et al. 2002). The detachment of pericytes is even 
thought to promote the development of cancer (Hosaka et al. 2016).  But the 
structural deficits of tumor vessels have another, considerably more dangerous 
consequence.  
The absence of pericytes, mural cells and a continuous basement 
membrane results in the loss of a physical barrier which under normal conditions, 
restricts the access to the blood stream. The large density of vessels lined with a 
thin basement membrane in a tumor statistically increases the chance of 
malignant cancer cells penetrating the vasculature and migrating to a distant site 
(Chang et al. 2000). In other words, a greater amount of structurally unsound 
blood vessels correlates with an increased incidence of metastases (Weidner et 
al. 1991). 
The correlation between angiogenesis and the increased incidence of 
metastasis is also illustrated by the fact that tip cells promote the synthesis of 
metalloproteases that break down the matrix and thereby facilitate the escape of 
motile neoplastic cells through the vasculature. In conclusion, pathological 
angiogenesis is detrimental for three major reasons. First and foremost, the 
proliferation of angiogenic sprouts into the tumor allow it to grow. Next, the rapid 
expansion of the vasculature is poorly regulated and leads to abnormal blood 
flow, which in turn causes the appearance of necrotic areas within the tissue. 
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Finally, and perhaps most importantly, pathological angiogenesis is correlated 
with the dissemination of cancer cells into the blood stream, a process called 
metastasis, which significantly worsens the prognosis. The concept of metastasis 
will be explained in greater detail in the following sections. 
 
Angiogenic Regulators 
Physiological angiogenesis is directed by the release of several pro-
angiogenic molecules, which include growth factors, chemokines and enzymes. 
The most relevant and important candidates from this list will be discussed in this 
section. Vascular endothelial growth factor A (VEGFA) is undoubtedly the most 
famous of all angiogenic regulators. In 1983, Dr. Harold Dvorak isolated and 
identified a soluble peptide which he named vascular permeability factor, due to 
its potent permeabilization effect on blood vessels, as its name would suggest 
(Dvorak et al. 1983). The molecule was renamed VEGF and is now known to 
orchestrate a wide variety of vascular-related events. Its presence is so important 
for the formation of a functional vascular system that heterozygous knockouts are 
embryonically lethal at E8 (N. Ferrara et al. 1996).  
Alternative splicing of VEGF mRNA leads to the formation of a multitude of 
variants, each of which demonstrates specific binding affinities and biological 
properties (He et al. 1999). The most common one, VEGF165, is pro-angiogenic 
and plays a crucial role in endothelial cells proliferation during development and 
adulthood. It contains a binding site for a family of glucosaminonglycan 
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molecules, including heparin and heparan sulfate (Zhao et al. 2012). As a 
consequence the secretion of VEGF from a point source within a tissue will 
cause the growth factor to bind these polysaccharides, leading up to the 
formation of a gradient, in which the greatest concentration of VEGF is found 
closest to the source from which it was released, as depicted in Figure 1 
(Gerhardt et al. 2003).  
 
Figure 1: Formation of a new vessel sprout. The formation of a VEGF gradient 
from a point source guides the direction in which the blood vessel sprout 
proliferates. Bielenberg et al., unpublished. 
The gradient allows the precise guiding of the angiogenic sprout towards 
the area of the tissue that requires perfusion. Given that many neoplastic cells 
secrete large quantities of VEGF (amongst other growth factors)  in a tumor, the 
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precise guiding of the tip cells is replaced by the chaotic proliferation of 
endothelial cells in multiple directions, leading up to the formation of tortuous and 
malformed vessels, as described in previous sections (Dvorak et al. 1983, 
Aaronson 1991).  
Like any regulated biological process, angiogenesis is also controlled by 
endogenous inhibitors. Dr. Judah Folkman and Dr. Bruce Zetter discovered that 
interferon inhibits the proliferation of the tumor stimulated endothelial cells 
(Brouty-Boyé and Zetter 1980). Another endogenous inhibitor of angiogenesis is 
thrombospondin, a secreted glycoprotein that was discovered by Dr. Jack Lawler 
(Lawler, Slayter, and Coligan 1978). The pro-apoptotic role of thrombospondin is 
essential to induce the remodeling of the vascularization and keep the 
proliferation of blood vessels in check (Mirochnik, Kwiatek, and Volpert 2008).  
However, in the context of this thesis, the most relevant endogenous inhibitor of 
vascular proliferation is undoubtedly semaphorin3F (SEMA3F). This secreted 
protein is part of a vast family of molecules, with very diverse biological functions, 
ranging from nerve guidance to the regulation of angiogenesis. Semaphorins will 
be discussed in much greater detail in subsequent sections.  
 
In summary, the process of endothelial proliferation is a precisely orchestrated 
mechanism, guided by the secretion of pro and anti-angiogenic molecules. The 
homeostatic balance of these factors is lost in disease states like cancer, leading 
to the formation of tortuous vessels. As a consequence, as Dr. Judah Folkman 
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recognized many decades ago, the endogenous orchestrators of angiogenesis 
can be targeted to inhibit the growth of tumors and their dissemination to distant 
sites. The concept of anti-angiogenic therapies will be discussed in further detail 
in the next section. 
 
Anti-Angiogenesis in Cancer  
Considering that angiogenesis is indispensable for the growth and 
dissemination of tumors, there is great incentive in developing anti-angiogenic 
therapies to combat cancer.  Dr. Judah Folkman came to this realization more 
than 40 years ago when he pioneered the field of angiogenesis research. Dr. 
Folkman’s philosophy is based on a number of assumptions that have stood the 
test of time and are still valid to the process of anti-angiogenic drug development. 
Based on the failures and limitations of previous cancer chemotherapeutics, he 
knew that drugs should not be designed to target the tumor cell itself. Indeed, 
due to frequent mutations, cancer cells are likely to develop chemotherapeutic 
resistance mechanisms, thereby rendering certain treatment options ineffective 
(Housman et al. 2014). On the other hand, the chances of such mutations 
occurring spontaneously in healthy, non-neoplastic tissue such as the 
endothelium, is virtually zero. As a consequence, anti-angiogenic therapies 
should target endothelial cells in order to limit the growth of tumors, while 




Figure 2: Timeline of antiangiogenic drug discoveries from the Folkman 
lab. Discovery of anti-angiogenic molecules between 1980 and 2005. 
 
This concept explains the failure of perhaps the most widely known anti-
angiogenic therapy, namely bevacuzimab, a monoclonal antibody directed 
against the most important and famous promoter of angiogenesis, VEGF-A. 
While bevacizumab showed great potential during the clinical trials prior to its 
approval by the FDA in 2004, its use remains limited for certain types of cancers 
and overall, the results have fallen short of its expectations (Vasudev et al. 
2014).  
Speculation about the shortcomings of bevacizumab raised a number of 
questions. Perhaps there are severe limitations in mouse xenograft models, the 
likes of which depicted bevacizumab as a wonder drug during preclinical trials 
(Kim et al. 1993). Others would argue that the flaw lies within the idea that this 
monoclonal antibody is directed against VEGFA, a growth factor produced in 
abundance by the tumor cells. Therein lies the true weakness of bevacizumab, 
namely the fact that it is directed against an element of the disease that the 
tumor can evade through mutation and adaptation, thereby violating one of the 
cardinal rules of anti-angiogenic drug development according to Dr. Folkman.  
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However, an excess of 40 years of angiogenesis research have not culminated 
into the development of a single drug.  
The failure of bevacizumab to live up to its expectations should not be 
perceived as the collective downfall of this particular field of research. There are 
multiple endogenous inhibitors of endothelial cells that have yet to be fully 
explored, all of which could potentially fulfill Dr. Folkman’s true vision of anti-
angiogenic therapy. One of those inhibitors will be the main focus of this thesis 
project and will be introduced in greater detail below. 
 
VEGF Receptors 
The vascular endothelial growth factor receptors 1,2 and 3 (VEGFR1,2,3), 
as their names indicate, are primarily involved in regulating angiogenesis (Dvorak 
2002). VEGFR1 and 2 are composed of seven extracellular immunoglobulin 
domains whereas VEGFR3 only has six, but all of them include a single 
transmembrane domain. The intracellular part of the proteins contains a tyrosine 
kinase domain and as a consequence, VEGFRs are considered a part of the 
receptor tyrosine kinase (RTK) family of molecules (Muller et al. 1997). Upon 
binding to their ligand, RTK’s form homo-or hetero-dimers. This conformational 
change allows the phosphorylation of the cytoplasmic tyrosine residues on the 
receptors, a crucial step in signal transduction (Hubbard and Miller 2007). 
Differential expression of these receptors, as well as different binding 
affinities for a variety of VEGF-associated family members during development 
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and adulthood illustrates their respective importance as mediators of pathological 
and physiological angiogenesis. For example, VEGFR1 preferentially binds 
VEGF-A, VEGF-B and placenta growth factor PGF, whereas VEGFR2 binds 
VEGFA, cleaved VEGFC, cleaved VEGFD and VEGFE (Napoleone Ferrara, et 
al. 2003). VEGFR3 on the other hand only binds VEGFC and VEGFD. 
Furthermore, VEGFR1 is expressed on endothelial cells, macrophages, 
osteoblasts, renal mesangial cells and hematopoietic stem cells. The distribution 
of VEGFR2 overlaps somewhat with that of VEGFR1, but it is also found on 
neuronal cells and megakaryocytes. 
In terms of angiogenesis, the most important interaction occurs between 
VEGFA and VEGFR2. It leads to the migration and proliferation of endothelial 
cells by signaling through AKT or ERK (Dellinger and Brekken 2011). VEGFR1 
on the other hand is now thought to act as a decoy receptor, meaning that it is 
capable of binding VEGF isoforms, but lacks the ability to activate a signaling 
pathway (Meyer, et al. 2006). 
The distinguishing feature of VEGFR3 is its abundance in lymphatic 
endothelial cells (LEC), illustrating its role in lymphangiogenesis and mediating 
certain immune functions. VEGFR3 controls the proliferation of LEC primarily by 
binding VEGFC and its importance in maintaining a healthy lymphatic system is 
perhaps best illustrated by the fact that some patients suffering from primary 
lymphedema carry a missense mutation in the gene that encodes the receptor 
(Karkkainen et al. 2000). VEGFR3 is primarily expressed on sinusoids in the liver 
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There is another class of VEGF binding molecules, other than the 
traditional RTK like VEGFR called neuropilins (NRP). NRP1 and NRP2 are 
transmembrane proteins that were discovered by Fujisawa and Chen, 
respectively, as mediators of neuronal development in embryos (Fujisawa et al. 
1998, Chen et al. 1997). The role of Nrp1 in vascular biology was quickly 
established after transgenic (overexpression) and knockout (deletion) mice 
showed dramatic vascular defects with embryonic lethality (Kitsukawa et al. 
1995, Kawasaki et al. 1999). Nrp2 knockout mice showed defects in lymphatic 
vessel sprouting (Yuan et al. 2002, Xu et al. 2010).  
In humans, NRP1 maps to chromosome 10, and NRP2 maps to 
chromosome 2 (Rossignol et al. 2000). Both NRPs have a similar size and 
structure with greater than 44% homology. The transmembrane receptors are 
130 kDa and made up of five extracellular domains (a1, a2, b1, b2, c), a 
transmembrane domain and a small intracellular cytoplasmic domain (reviewed 
by Bielenberg et al. 2006).  
There is only one NRP1 receptor isoform, whereas there are two NRP2 
isoforms called NRP2a and NRP2b. The C-terminal 3 amino acids of NRP1 and 
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NRP2a are identical (S-E-A) and confer binding to the PDZ-domain in synectin, a 
cytoplasmic scaffolding protein (Tao et al. 2003, Cai et al. 1999). 
NRP2b has a shorter cytoplasmic region that lacks the synectin-binding motif. 
Soluble versions of the two receptors are the result of naturally-occurring splice 
variants, consisting only of the extracellular ligand-binding a1a2 and b1b2 
domains. The soluble proteins act as antagonists to their transmembrane 
counterparts (Gagnon et al. 2000, Panigrahy et al. 2014). 
 
Neuropilin Ligands and Signaling 
NRP1 and NRP2 differ in their expression pattern and their affinity for 
various pro-angiogenic VEGF family members. NRP1 preferentially binds to 
VEGFA, B, or E and PGF2. NRP2, on the other hand, binds VEGFA, C, or D and 
PGF2 (Klagsbrun et al., Mamluk 2002, Favier et al. 2006). The short intracellular 
domain of NRPs make them incapable of signaling on their own after binding 
VEGF, which means that NRPs have to form a complex with other 
transmembrane receptors. As a consequence, upon binding to the b1/b2 region 
of NRPs, VEGFs create a bridge between the NRP and VEGFR (Soker et al. 
1998). The domain of VEGFA that is encoded by exon 4 binds to VEGFR2, while 
the domain that binds NRP1/2 is encoded by exon 7 (Soker et al. 2002).  
VEGF is capable of signaling through VEGFR in the absence of NRP, but 
it has been shown that the NRP/VEGFR complex increases the affinity of 
VEGFR for its ligand and holds the complex on the cell surface and endosome 
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longer, thereby increasing the degree of phosphorylation of the tyrosine kinase, 
which itself leads to an increase in the intensity of the pro-angiogenic signal.  
NRPs also bind a family of secreted guidance proteins called class 3 
semaphorins (SEMA3), which consists of SEM3A, B, C, D, E, F, and G as 
reviewed by Gaur et al. (Gaur et al. 2009).  
SEMA3s were initially named collapsins, due to their role as axonal 
guidance molecules and their ability to collapse the growth cone on the end of 
the axon (Kolodkin, Matthes, and Goodman 1993a). In contrast to VEGF, binding 
to SEMA3s occurs at the NRP a1a2 and b1 domain, thereby partially overlapping 
with the VEGF binding region, b1b2 (Miao et al. 1999). NRP1 has a greater 
affinity to SEMA3A than does NRP2, whereas NRP2 preferentially binds 




Figure 3: Neuropilin 2 structure and ligands. VEGF binds neuropilin 2 and 
forms a bridge with VEGFR. Class 3 semaphorins bind neuropilin 2 and allow the 
formation of a complex with a plexin. Bielenberg et al., unpublished.  
 
 
In the case of SEMA3s, a complex is formed between the SEMA3, NRP,  
and another group of transmembrane receptors called plexins. Plexins are large 
transmembrane proteins that contain a “sema” domain in their extracellular 
region and a large cytoplasmic domain which includes protein binding regions 
and a GTPase activating protein (GAP) domain.  
Plexin A (1-4) and Plexin B (1-3) proteins are known to interact with NRP, 
but the exact singling mechanism has not been worked out for each protein-
protein interaction (Tamagnone et al. 1999). Furthermore, plexins lack kinase 
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activity but they are capable of associating with RTKs (Giordano et al. 2002). 
However, one of these receptor-ligand interactions, is quite well studied, namely 
the one between SEMA3F and PlexinA1. SEMA3F binds NRP2, allowing it to 
form a complex with PlexinA1. This complex then attracts the Abl2 tyrosine 
kinase, which activates p90rhoGAP, causing the inhibition of RhoA. Given that 
RhoA is a small GTPase, the conversion of GTP to GDP is blocked, ultimately 
leading to the depolimerization of f-actin, as depicted in Figure 4 (Nakayama et 
al. 2015). Depolymerized actin is associated with a reduction in migratory activity 
in both endothelial and tumor cells (Shimizu et al. 2008). 
 
 
Figure 4: Signaling cascade resulting from SEMA3F/NRP2/Plexin A1  
complex formation. Activation of ABL2 inhibits p190RhoGAP, which ultimately 
leads to the depolimerization of actin. The collapsed scaffold within the cell 
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Figure 4: Signaling cascade resulting from SEMA3F/NRP2/Plexin A1 
complex formation. Activation of ABL2 inhibits p190RhoGAP, which ultimately 
leads to the depolimerization of actin. The collapsed scaffold within the cell 
prevents it from migrating or dividing. Bielenberg et al., 2015.  
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SEMA3F can also signal through another pathway, which leads to the inhibition 
of the AKT and mTOR pathways, particularly in endothelial cells. The exact 
details of the pathway remain unclear, but the effects on the cell’s ability to 
migrate is indisputable (Nakayama et al. 2015). 
As mentioned above, the binding regions of class 3 semaphorins and 
vascular endothelial growth factor overlap on NRP. This is true for both 
SEMA3A/VEGF on NRP1 and SEMA3F/VEGF on NRP2. Furthermore, SEMA3F 
and VEGF bind NRP2 with very similar affinities. As a consequence, there is 
competition between the two molecules and binding to NRP2 is almost 
exclusively dictated by concentration (Geretti et al. 2007). Interestingly, both 
class 3 semaphorins and vegf isoforms will bind heparin sulfates on the cell 
surface. The binding to these glycosaminoglycans facilitates protein interactions 
and helps sustain the resulting signaling cascade (Krilleke et al. 2007).   
Given these observations, there is one important conclusion to draw from 
the competitive nature of these two ligands, if one is to exploit the anti-angiogenic 
effects of SEMA3F for therapeutic purposes. While SEMA3F inhibits the 
proliferation of endothelial cells by forming a complex with NRP2 and PlexinA1, it 
does not affect the binding of VEGF to VEGFR2. This is a considerable 
disadvantage to other potential therapeutic options that are much more efficient 




However, as previously discussed, VEGFA failed to deliver on its 
promises, mainly because it targets a growth factor that is produced in 
abundance by the tumor cells, which due to frequent mutations, are able to 
eventually adapt and evade the effects of the drug. On top of being more in line 
with Dr. Folkman’s philosophy on anti-angiogenic drug development, SEMA3F 
offers another very appealing quality, namely its ability to mediate repulsion. The 
repulsive abilities of SEMA3F will be discussed in greater detail in the following 
section.  
 
SEMA3F and Repulsion 
Due to their ability to induce the collapse of an axonal growth cone, class 
3 semaphorins were initially almost exclusively studied as neuronal guidance 
molecules (Kolodkin, et al. 1993b). Their role as molecular guides implies that 
the direction from which they are secreted matters greatly. During development 
for example, NRP2-expressing neural crest cells migrate in a precise pattern 
along the somites, depending on the presence or absence of SEMA3F (Gammill 
et al. 2006). These results were also observed in-vitro, when NRP1-positive 
dorsal root ganglia and NRP2-positive superior cervical ganglia (SCG) 
experienced repulsion from point sources emitting SEMA3A and F (Masuda et al. 
2004, Giger et al. 2000).  
The Bielenberg laboratory discovered that SEMA3F can also act as a 
repellent on endothelial cells (Bielenberg et al. 2004a). The way SEMA3F acts as 
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a mediator of repulsion works through actin depolymerization, which results in 
the collapse of the cell, as described in the previous section. There is speculation 
on whether SEMA3F is capable of repelling any cell expressing NRP2, but 
nonetheless, this topic is of great interest to this project, given that NRP2 is also 
found on certain types of cancer cells. NRP2 expression in cancer will be 
discussed in greater detail in subsequent sections.  
 
Pancreas 
Given that this thesis project focuses on the discovery of novel therapeutic 
approaches for the treatment of pancreatic cancer, the following section will 
describe the basic function and structure of the pancreas. The pancreas is a 
glandular organ and is divided into four parts including the head, neck, body and 
tail. The head is wedged in between the C loop of the duodenum and in front of 
two major blood vessels, namely the inferior vena cava and the left renal vein. 
The body and tail both lie in front of the aorta and the left kidney.  
From a histological perspective, it is composed primarily of acinar and 
ductal epithelial cells, which together fulfill the exocrine function of the organ. 
Acinar cells are organized in lobules and surround the lumen of a ductule, into 
which they secrete zymogens and other digestive enzymes, following stimulation 
from hormones such as secretin and cholecystokinin. The ductal cells 
themselves secrete bicarbonate, making the pancreatic juice slightly alkaline. 
The ductules collect into progressively larger ones, which eventually empty into 
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the pancreatic duct. The bile duct joins the main pancreatic duct thereby forming 
a common channel called the ampulla, which opens at the major duodenal 
papilla, allowing the delivery of pancreatic juices along with bile to the chyme. 
The endocrine function of the pancreas is carried out by cells located within 
patches of specialized cells called islets of Langerhans. These islets are 
interspersed throughout the parenchyma of the organ and include alpha, beta 
and gamma cells, which synthesize and secrete glucagon, insulin and 
somatostatin respectively. These hormones regulate a number of vital functions 
mainly relating to blood sugar levels and the maintenance of metabolic 
homeostasis. Nerve supply is primarily parasympathetic in nature and originates 
from the celiac branch of the posterior vagal trunk and regulates the release of 
endocrine and exocrine hormones. 
 





As discussed, the endocrine and the exocrine functions of the pancreas 
are carried out by different groups of cells and as a consequence, there are two 
major classes of pancreatic cancer which can also be divided into exocrine and 
endocrine (Compton et al., 2012). The former is by far the most common type 
and in 95% of the cases they arise from ductal cells, which further classifies them 
as pancreatic ductal adenocarcinomas (PDAC). The remaining 5% arise from 
acinar cells and are consequently called acinar cell carcinomas. Endocrine 
tumors are much rarer and can be either malignant or benign, and are referred to 
as a pancreatic neuroendocrine tumors (NET) or insulinoma  (Kleeff et al. 2016, 
Oberg et al. 2005). If a NET leads to an overproduction of hormones that causes 
symptoms, the NET is classified as a functioning tumor, while NETs that do not 
produce noticeable changes in hormone production are referred to as 
nonfunctioning. 
Making up only 3% of all diagnosed cancers in the US, PDAC accounts for 
7% of all cancer related deaths. The high mortality rate of PDAC is due to a 
number of reasons (R. L. Siegel, Miller, and Jemal 2015).First and foremost, 
there are no preventive screening methods, which makes the diagnosis of the 
tumor very difficult (Hidalgo et al. 2015). The absence of noticeable symptoms 
during the rapid growth of the tumor leads to a late detection of the disease, at 
which point the diagnosis is relatively poor (Dimastromatteo et al. 2015). About 
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90% of patients suffer from local invasion and distant metastases at early stages 
of the disease (R. Siegel et al. 2011). 
The tendency for pancreatic cancer to metastasize at very early stages of 
the disease reduce the number of curative tumor resections to about 20% (Kleeff, 
Korc, Apte, La Vecchia, et al. 2016). Pharmaceutical treatment of pancreatic 
cancer is currently limited to gemcitabine and 5-fluoruracil, both of which have 
failed to significantly increase survival (Stathis and Moore 2010).  
In PDAC, much like in other types of cancer, patients die as a result of 
metastases, not necessarily the primary tumor itself (Ahrendt and Pitt 2002). A 
particularly common metastatic site for PDAC is the liver, primarily due to the 
pancreas’ proximity to major blood vessels such as the portal vein, the celiac 
trunk and the superior mesenteric artery (Paik et al. 2012).  
Therefore, there is an urgent need to find new therapeutic options capable 
of fighting not only the primary tumor, but also its dissemination to distant sites 
such as the liver. The following section will explore the potential of SEMA3F as a 
potential candidate in the quest to find new therapeutic approaches to fight 
PDAC. 
 
NRP2 Expression in Cancer and The Therapeutic Potential of SEMA3F 
NRP2 expression is upregulated in a number of different cancers. An 
increase in NRP2 expression has been observed in certain types of primary non-
small-cell lung carcinomas, primary breast carcinomas, melanomas and primary 
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colorectal cancers (Fukahi et al. 2004, reviewed by Bielenberg and Klagsbrun 
2007).  
Given the fact that primary tumor growth and metastasis is angiogenesis 
and lymphangiogenesis dependent, the expression of Nrp2 has been shown to 
be elevated on the endothelial cells of the tortuous blood vessels and lymphatics 
that perfuse the tumor (Staton et al. 2007).  In order to investigate Nrp2 as a 
potential treatment target, Bielenberg and colleagues (2004b) have shown that 
melanoma cells transfected with the Nrp2 inhibitor SEMA3F have a reduced 
incidence of metastasis. In the same study, the anti-angiogenic effects of the 
SEMA3F protein were illustrated by the large number of apoptotic cancer cells 
within the tumor (Bielenberg et al. 2004b).  Similar results were subsequently 
observed by other labs who studied the role of SEMA3F in different cancers 
(Kigel et al. 2008, Kessler et al. 2004, Nakayama et al. 2015). In yet another 
preclinical study in mice, it was shown that the use of an anti-NRP2B antibody 
reduced lymphangiogenesis and the number of metastases in the lung, a 
common seeding site for migrating neoplastic cells (Caunt et al. 2008).  
Dallas et al. have shown that by knocking-down the expression of NRP2 in 
human PDAC cells using a stable short hairpin RNA prior to injection in vivo, they 
managed to limit migration and proliferation of cancer cells in subcutaneous and 
orthotopic xenograft models in immunodeficient mice (Dallas et al. 2008). This 
finding is important for two reasons. On one hand they indicated that by silencing 
NRP2 expression in-vivo, they were capable of influencing tumor growth. On the 
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other hand, their study showed that the silencing of NRP2 did not influence the 
growth of PDAC cells in-vitro, indicating that NRP2 does not act as an autocrine 
receptor for VEGF.  
By knocking down NRP2 expression in-vivo however, they also observed 
a decrease in tumor microvessel density. As a consequence, tumor growth was 
limited in-vivo primarily due to the anti-angiogneic effect of inhibiting NRP2 
expression.  
These results are reminiscent of previous experiments in which NRP1 was 
inhibited in tumors, suggesting that tumor-derived NRPs guide the proliferation of 
endothelial cells into the tumor microenvironment, potentially by binding VEGF 
and creating a gradient into the heart of the tumor (Miao et al. 2000, Parikh et al. 
2004). 
In conclusion, these observations illustrate the potential of using NRP2 as 
a novel drug target, both on the tumor cells themselves and the tumor 
endothelium, for the treatment of PDAC.  
 
Liver Metastasis 
In 1889, a British surgeon by the name of Stephen Paget, made an 
important observation that has shaped the field of cancer research for more than 
a century. After studying 735 cases of breast cancer, he found that the vast 
majority of the patients had died from metastases that had primarily migrated to 
the liver and the lung (Paget 1889). He then famously postulated his “seed and 
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soil” hypothesis, which refers to the fact that a certain type of cancer cell (seed), 
will preferentially metastasize to a specific distant organ (soil), instead of causing 
secondary growths in random parts of the body. A graphical depiction of the 
metastatic cascade is depicted in Figure 6.  
 
Figure 6: Depiction of the metastatic cascade from the primary tumor site 
to the distant organ into which neoplastic cells migrate. The figure depicts 
the process of metastasis from transformation to the migration to a common 
metastatic site like the lung.  
 
The liver is a very common metastatic site for numerous cancers, 
including PDAC. The   extensive perfusion of the liver by large vessels like the 
portal vein, or the presence of relatively permeable sinusoids throughout the 
parenchyma might contribute the elevated incidence of metastases within this 
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particular organ. But the mechanical-anatomical features of the liver are not the 
only reasons for why it is such a fertile soil for distant metastases. The 
expression of certain genes, including chemokines and receptors are correlated 
with the incidence of secondary tumor growth in the liver as reviewed by Fidler et 
al. ( Fidler et al. 2011). 
There are a number of interesting features about the liver that need to be 
discussed in the context of this thesis project. The first consideration revolves 
around the expression of NRP2 in the adult body. NRP2 is downregulated on 
endothelial cells, but its expression is increased during inflammation or ischemia 
(Mucka et al. 2016). The receptor is also found on smooth muscle cells within the 
intestinal tract and the bladder. In the liver on the other hand, NRP2 expression 
is absent (Bielenberg et al. 2012). Figure 7 indicates the absence of NRP2 




Figure 7: Western Blot and IHC of Nrp2 expression in different cells. (A) 
Western blot showing the expression of Nrp2 in certain tissues including the 
uterus, skin, lung, intestine and brain. (B) Immunohistochemistry performed in a 
mouse liver revealing the absence of Nrp2. 
 
Considering that this thesis project revolves around the therapeutic use of 
SEMA3F, the fact that the liver does not express NRP2 is likely beneficial. In fact, 
the absence of the receptor probably mitigates the incidence of unwanted side 
side effects on healthy hepatocytes. A second consideration to make is that an 
adenovirus was used to induce the expression of SEMA3F in the liver. 
Adenoviruses have a tendency to infect the liver, which is where we need the 
expression of SEMA3F to be the highest in order to analyze its effect on the 
development of liver metastases.   
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In conclusion, there is a dire need to treat the formation of metastases in 
the liver in PDAC. The aggressiveness of the disease coupled with a lack of 
effective treatment options adds another degree of translational significance to 
our work.  
 
Mouse Pancreatic Cancer Models and Experimental Design 
There are currently for different kinds of PDAC models performed in mice. 
They can be classified based on whether they are based on the use of human or 
mouse cell lines. One of the most commonly used models relies on the use of 
human cells in immunodeficient mice. There are many ways to establish a mouse 
model that lacks a functioning immune system. There are for example, “nude” 
mice which carry a spontaneous mutation of a gene that regulates the formation 
of the thymic epithelium. The lack of a thymus in nude mice causes them to 
suffer from the absence of functional T cells (Nehls et al. 1994).  
On the other hand, there are severe combined immunodeficient mice 
(SCID) with lack both B and T cells due to a spontaneous mutation in a gene that 
regulates the development and maturation of lymphocytes (Bosma, et al. 1983). 
Finally there is a newly developed strain called NOD/SCID/gamma (NSG), which 
lack B,T and NK cells (Cao et al. 1995).The absence of a functioning immune 
system in these mice makes them very suitable for the transplantation of human 
xenogeneic tissue. A good example such as study is the one by Dallas et al., in 
which immunodeficient mice were injected with human BxPC3 PDAC cells. 
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(Dallas et al. 2008). There is a slight variant to these xenograft models, which 
revolves around the use of patient-derived grafts (PDX) mode, instead of using 
human cell lines (Siolas et al. 2013). 
While using human cells certainly elevates the translational significance of 
the study, there are a number of downsides to using human xenografts. The 
most obvious of these problems is the absence of a fully functioning immune 
system, which plays an important role in the development and treatment of 
cancer. Furthermore, the frailty exhibited by immunodeficient mice, make them 
less tolerant to the type of cancer therapeutics that would normally be 
administered to a human patient (Sharpless et al. 2006). Lastly, immunodeficient 
mice are very expensive with NSG mice over $200/mouse (Jackson Labs). 
The two most common ways of generating mouse pancreatic cancer in a 
mouse are either by using transgenic animals in which a promoter of choice 
drives the expression of an oncogene or by injecting mouse PDAC cells into a 
syngeneic mouse. There are pros and cons to either of these models. The most 
common transgenic PDAC model involves the expression of a Cre recombinase, 
which is driven by a pancreas-specific gene such as the transcription factor 
PDX1. This mouse would then need to be crossed with another mouse, which 
possesses a mutated Kras, which itself is preceded by a floxed stop codon. The 
resulting F1 would then further need to be crossed in order to generate a Cre +/-, 
flox +/+ F2 mouse. The Cre recombinase would then splice put the stop codon 
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preceding the mutated Kras only in pancreatic cells, which would then lead to the 
formation of pancreatic cancer (Westphalen et al.  2012). 
On top of the obvious financial and logistical cost of creating such a 
mouse, transgenic oncogene-driven pancreatic cancer models are similar to the 
human disease in that they progress relatively slowly over many weeks and 
progress through stages similar to pancreatic intra-epithelial neoplasia (PanIN) 
and eventually to PDAC, but have proven to fail to reflect certain genetic 
characteristics of PDAC (Bardeesy et al. 2006).   
Based on these considerations, we decided to use a syngeneic orthotopic PDAC 
model in C57/BL6 mice. As described in the methods section, we used a mouse 
pancreatic cancer cell line called Panc0H7, which was provided by Dr. Keping 
Xie from M.D. Anderson Cancer Center in Houston, Texas. Panc0H7 cells were 
generated during an experiment aimed at trying to understand the role of nitric 
oxide in tumor growth. Mouse pancreatic cells were incubated in a number of 
chemokines and interferon in-vitro prior to being injected orthotopically in mice. 
Clonal sublines that expressed low levels of nitric oxide synthase caused the 











All cell lines were incubated at 37°C. Human cells were kept at 10% CO2 and 
mouse cells were kept in 5% CO2. The volume of media per dish varied 
depending on the size of the dish with 20 ml/15 cm dish, 10 ml/10 cm dish, 2 ml/6 
well, and 0.5 ml/24 well.  
 
1) Panc0H7 
Panc0H7 is a mouse PDAC cell line that was obtained from Dr. Keping Xie 
(M.D. Anderson Cancer Center, Houston, Texas) (B. Wang et al., 2003). 
Panc0H7 is syngeneic for C57BL6 mice and was used in all our isograft 
preclinical trials. For select experiments, Panc0H7-luc cells were obtained from 
Dr. Randy Watnick (Boston Children’s Hospital, Boston, MA). Panc0H7-luc was 
created by retroviral transduction using a neomycin selection cassette by Dr. 
Andrew Kung (Dana Farber Cancer Institute, Boston, MA). The cells were plated 
in Dulbecco’s Eagle Media with 10% fetal bovine serum (FBS) and 1% penicillin-







Human embryonic kidney cells (HEK293) are spontaneously immortalized 
cells that were transformed in the 1970’s by a group of scientists who infected 
the cells with a human adenovirus 5. The cells incorporated a portion of the viral 
genome including genes E1 and E3. E1 encodes proteins involved in the 
replication of the virus, which makes HEK293A a perfect option to amplify the 
stock concentration of replication-incompetent SEMA3F adenovirus in this 
project. Furthermore, the cells were used to quantify the SEMA3F virus as 
described in the titer procedure. HEK293A cells were purchased from 
ThermoFisher Scientific. The cells were grown in Dulbecco’s Eagle Media with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-gluatamine (GPS). 
 
3) hTerT  
Human urothelial cells (hTerT) are an immortalized cell line that were 
developed by Dr. Jayoung Kim (Boston Children’s Hospital, Boston, MA). The 
main feature of these cells is that they are epithelial cells and are therefore 
particularly suited for infection by adenoviruses and were consequently used in a 
variety of virus related experiments.   The cells were grown in Dulbecco’s Eagle 








A special cryopreservation medium, containing 7 ml of media, 1ml of dimethyl 
sulfoxide (DMSO) and 2 ml of fetal calf serum was used to store the cell lines in 
liquid nitrogen. Following trypsinization, the cells were spun down at 5000 RPM 
for 15 minutes. The media was then removed and the pellet was re-suspended in 
freezing media. The cells were transferred in 1 ml aliquots to 10 cryopreservation 
vials (Corning). The vials were then moved to a Mr. Frosty device 
(ThermoScientific) which slows the freezing of the cells to less than -1°C/minute 
and stored in a -80°C freezer overnight, before finally being transferred to a liquid 
nitrogen tank for long term storage.  
 
Protein Isolation  
Cells were grown to a confluence of about 70-80% at which point the 
dishes were removed from the incubator and the media was discarded. The cells 
were washed with phosphate buffered saline (PBS) [137 mM NaCl, 2.7 mM KCl, 
8 mM Na2HPO4, and 2 mM KH2PO4; pH7.2-7.4]. In an effort to stop protein 
degradation within the cells, a cOmpleteTM mini protease inhibitor tablet (Sigma-
Aldrich) was dissolved in 10ml of radioimmunoprecipitation assay (RIPA) buffer 
[20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-
40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-
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glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin ](New England BioLabs). 
Cell Lysis/Protein Isolation solution (100ul) was added to the cells and the lysate 
was transferred to a microfuge tube using a cell scraper (Sarstedt). The whole 
cell lysated was incubated on ice for one hour and then centrifuged in a cold 
room at 10,000 RPM for 10 minutes. Finally the supernatant containing the 






1) Expansion of Viral Stocks  
The expression of human SEMA3A in C57/BL6 mice was achieved using a 
His-tagged human SEMA3A adenovirus. In order to maximize the expression of 
recombinant protein while at the same time reducing the risk of replication and 
infectivity, a second generation serotype 5 adenovirus (Ad5) lacking the early 
region 1 and 3 (E1 and E3) of the viral genome. E1 is a transcription factor 
necessary for viral replication, which limits the use of the replication-deficient Ad5 
to the infection of human embryonic kidney (HEK293A) cells. Sequence 
homology between the genome of HEK293A cells and Ad5 results in the 
formation of a transgene following transfection, which generates an RCA or 
replication competent adenovirus. Removal of the E3 gene on the other hand 
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leads to rapid clearance of the virus from the host, which makes Ad5 the perfect 
candidate for the intense but transient synthesis of recombinant protein, in this 
case, human SEMA3F.  
His-tagged human SEMA3F encoding adenovirus (catalog #129755A) and 
control Adeno CMV Null Adenovirus (catalog #000047A) was purchased from 
Applied Biological Materials, Inc. The stock virus (250ul at 1x106 pfu) was 
aliquoted and frozen. A series of serial infections were performed in order to 
amplify the titer and volume of the virus. The detailed procedure follows. 
On day one of the procedure, 4 dishes of HEK 293A cells were plated, two 10cm 
dishes were seeded with 1.5x106 cells and two 15cm dishes were seeded with 
3.0x106 cells. The first infection occurred on day 3, by adding 20uL of low titer 
viral stock to one of the 15 cm dishes plated on day 1.  
In order to expand the HEK293A cell line, two of the 15cm dishes from 
day one that reached 100% confluence on day 5 were plated into twelve 15 cm 
dishes at 1.5x106 cells respectively. The second infection occurred on the 
following day. The media from the infected 10 cm dish from day 3 was collected 
and freeze-thawed three separate times. This process bursts the cell membrane 
open, allowing the virus to diffuse into the media. In order to separate the media 
from the cell debris, the media was spun at 2500g for 15 minutes. The 
supernatant containing the virus was then collected, distributed into 1 ml aliquots 
and frozen at -80°C (this is referred to as low titer stock). One of these aliquots 
was used in order to infect one of the 15cm dishes from day 3.  
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On day 8, the media from the infected 15 cm dish was collected, freeze/thawed 
three cycles and spun at 2500 g for 15 min. The supernatant containing the virus 
was added to the remaining twelve 15cm dishes from day 5. On day 10 the 
supernatant of all 12 infected dishes was collected and subsequently purified.  
 
2) Purification of Virus following Expansion from Stock  
After expansion of the adenovirus from a low titer stock and subsequent 
collection, the virus was subjected to a series of purification steps.  Media from 
the twelve 15cm dishes was collected in four separate Falcon tubes. The tubes 
were spun down and the majority of the supernatant was removed. The 
remaining media was pooled into a single Falcon tube. The media was then 
freeze-thawed three times in order to break open the cell membrane of the 
HEK293A cells, which would then allow the virus to diffuse into the media. Next, 
an aliquot of benzonase nuclease (1ul per 10 ml of media) was added to the 
tube, which was incubated at 37°C for 30 minutes. The benzonase nuclease 
catalyzes the breakdown of any contaminating DNA in the tube. Next, a Fast-
Trap Virus Purification and Concentration Kit (Millipore) was used according to 
the manufacturer’s instructions.  
 
Under a biosafety hood, a Steriflip-HV was attached to a vacuum source and 
used to perform an initial clarification of the media. During the dilution step, 
binding buffer was added to the solution. This was then followed by the 
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equilibration step, which consisted in rinsing the Fast-Trap virus filter with 25 ml 
of an equilibration buffer. Next, the media containing the virus was filtered 
through the equilibrated membrane. Washing was performed using 20 ml of 
washing buffer. The virus was then eluted from the membrane using 3ml of 
elution buffer. Finally, the 3ml of elution buffer was added to an Amicon Ultra 
Filter unit. The filter was spun at 1500 x g for a duration of 5 minutes. Another 3 
ml of phosphate buffered saline was added to the tube, which was then spun 
again for 5 minutes at 1500 x g. The resulting pure virus stock was aliquoted into 
100ul samples and stored in -80°C. 
 
3) Virus Quantification  
The purified virus was quantified using Adeno-X-Rapid Titer Kit (Clontech). 
The titer assay consisted of plating 1 ml of log-phase HEK293A cells at a 
concentration of 5 x 10^5 cells/ml in each well of a twelve well plate. A 10-fold 
serial dilution of purified virus was then prepared using PBS and ranging from a 
concentration of 10-2 to 10-8 and added to each well and incubated at 37°C and 
5% CO2 for 48 hours. After two days, the media was aspirated and the cells 
were briefly air-dried under the biosafety hood. Next the cells were fixed by 
carefully adding ice-cold methanol. The cells were incubated at -20°C for 10 
minutes. After aspirating the methanol, the cells were washed three times with a 
solution of PBS and endogenous proteins were blocked using a 1% bovine 
serum albumin (BSA) solution. A rat anti-hexon antibody (Company? ) was 
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diluted 1:1000 in the same PBS/BSA solution and added to each well in the 
plate, which was then incubated at 37°C for 1 hour. The wells were rinsed again, 
three times using the PBS/BSA solution.  
An goat? anti-rat antibody (company), conjugated to horseradish peroxidase 
(HRP), was then added to all the wells. The plate was incubated at 37°C for 1 
hour. Prior to aspirating the secondary antibody solution from the wells, a 
solution of 10X 3,3’ diaminobenzidine (DAB) was diluted to 1X in a stable 
peroxidase buffer. DAB reacts with the HRP and forms a brown precipitate. As a 
consequence, only the cells infected with virus should turn brown since the 
primary antibody binds hexon, a viral protein. Finally, the DAB solution was 
aspirated and the cells were rinsed with the PBS/BSA solution. Following the 
staining procedure, a minimum of three fields were counted at a magnification of 
200X (an objective of 20x on a microscope that already amplifies 10x). In order to 
avoid bias, the fields were chosen randomly. The mean number of positive cells 
was counted per field and the following equation was applied in order to 















1) Staining in Liver and Pancreas 
Immunohistochemistry was performed on different types of tissues and used 
for the detection of various antigens. Pancreatic tumor sections were stained for 
Ki67, CD31 and TUNEL. Ki67 is a cellular proliferation marker and its presence 
in the cell nucleus is indicative of the cell’s reproductive activity. As a 
consequence, an antibody directed against Ki67 was used with the intention to 
stain actively dividing cancerous cells within the pancreata of experimental and 
control treated mice. CD31, also called platelet endothelial cell adhesion 
molecule (PECAM1),  is an endothelial cell marker and antibodies directed 
against this protein stain all vascular structures including veins, arteries, 
capillaries, and lymphatic vessels.  
CD31 was used in order to quantify the microvessel density inside the tumor. 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining 
reveals fragmented DNA strands that result from cell damage, which itself is 
normally a consequence of apoptosis or necrosis. This staining method relies on 
an enzyme called terminal deoxynuclotidyl transferase to catalyze the addition of 
biotinylated dUTP’s to any DNA strands that have been “nicked” or damaged.  
Liver slides were stained with the intention to reveal pancreatic metastases.
 Considering that hepatocytes rarely replicate under physiological 
conditions, Ki67 was again used as a proliferative marker, considering that only 
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metastases were expected to indicate signs of growth. An antibody against  
pancreas/duodenum homeobox protein1 (PDX1) was also used. PDX1 is a  
transcription factor normally expressed in pancreatic cells and not in 
hepatocytes, therefore PDX1 staining was expected to reveal the presence of  
pancreatic metastases in the liver. Finally, liver slides were also stained with  
Nrp2 considering that the Panc0H7 cells that metastasize to the liver in our  
experimental model express the receptor. A list of each antigen and their specific  
IHC requirements are listed in Table 1.  
 
 
Table 1: IHC requirements for each antigen analyzed in this study. The table  
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2) Deparaffinization and Antigen Retrieval 
Given that every tissue analyzed by IHC in this project was formalin-fixed and 
paraffin embedded (10% buffered formalin for 18 hrs), the slides were first 
heated on a hot plate at 59°C, then deparaffinized by sequential submersion in 
xylene and decreasing percentages of ethanol (4 then 3 minutes in xylene, and 
2x2 minutes in 100%, 95%, 75%, 50% EtOH). The slides were then put in PBS 
for 5 minutes before moving on to antigen retrieval.  
The staining procedures used in this project included one of two antigen 
retrieval techniques described below. The first one consisted in the use of 
proteinase K (manufacturer), a non-specific enzyme that catalyzes the 
breakdown of crosslinks in a formalin-fixed tissue. Removing the crosslinks prior 
to staining is essential to facilitate the antibody-antigen interaction. The 
proteinase K was diluted 1:1000 in PBS from a 20 ng/ul stock solution and 
warmed in a water bath at 37°C. The enzyme was then added to the slide for a 
duration of 20 minutes at 37°C. 
The other antigen retrieval procedure is heat-induced. It involved the use of a 
pressure cooker (Boston Bioproducts) containing 500ml of ddH2O. A coplin jar 
filled with a 10mMol sodium acetate solution at a pH of 6 is containing the slides, 
is put into the water within the pressure cooker. The pressure cooker is then set 
to heat up to 120°C for 1 minute before cooling back down to room temperature 
(25°C). The slides are then put in PBS for 5 minutes before proceeding to the 
rest of the staining procedure. Here again, the goal is to remove the crosslinks 
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found a formalin fixed piece of tissue that interfere with the antibody-antigen 
interaction.  
 
3) Blocking Endogenous Enzyme Activity and Non-Specific Antibody Binding 
Following deparaffinization and antigen retrieval, the slides needed to be 
treated with two different blocking solutions. For IHC procedures that involved the 
use of a horseradish peroxidase (HRP), the slides needed to be submerged in 
3% H2O2 dissolved in methanol for a duration of 12 minutes, with the intention of 
blocking the activity of any endogenous peroxidase enzyme present in the tissue. 
Blocking endogenous peroxidases prevents the chromogen from reacting with 
enzymes other than the exogenous horseradish peroxidase added during the 
staining procedure.  
Furthermore, the slides were blocked using Tris-NaCl protein blocking buffer 
(TNB, ThermoFisher) for a duration of 30 minutes at 25°C. This prevents non-
specific binding of the primary and secondary antibody. The types of antigen 









4) Amplification Methods: ABC and Tyramide 
Two separate amplification methods were used in this project depending on 
the antigen of interest. The specific procedure for both is described below. 
 
4)a) ABC Amplification  
 
ABC stands for avidin, biotin and chromogen. The purpose of this staining 
technique is to amplify the signal generated by the chromogen. Following antigen 
retrieval and blocking, the primary antibody (diluted 1:200 in TNB) is added to the 
slide and kept at 4°C for 24 hours in a humidified chamber. The following day, a 
biotinylated secondary antibody is diluted 1:200 in TNB and added to the slide at 
25°C for one hour. In order to allow avidin to form an irreversible bond with biotin 
(Vectastain Elite, Vector), equal concentration of the two proteins are mixed 
together in PBS for 30 minutes prior to their addition to the slide.  
The chemical nature of the chromogen dictates the use of a specific type 
of biotin molecule. If the chromogen is a phosphate-based compound (Ferangi 
Blue and Vector Fast Red, Biocare Medical) then the biotin used in the procedure 
is linked to an alkaline phosphatase, which upon catalyzing the chromogen, 
generates the color of interest. On the other hand, if the chromogen is a 
peroxide-based compound (DAB, Vector), then the biotin used in the procedure 
is linked to an HRP. The types of amplification techniques for each antigen are 
listed in Table 1. 
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4)b) Tyramide Amplification 
 
Tyramide amplification, in contrast to the ABC procedure, adds another 
degree of amplification. This technique was exclusively used for CD31 staining. 
Following deparaffinization, blocking and the addition of the primary antibody 
(incubated at a concentration of 1:200 in TNB for 24 hours in a humidified 
chamber at 4°C) the biotinylated secondary antibody was added at room 
temperature (25°C) for 1 hour.  
Next, streptavidin HRP (MANUFACTURER) (diluted 1:100) in TNB is 
added to the slide for 30 minutes. After rinsing away the streptavidin, biotinylated 
tyramide is diluted in amplification buffer (1:50) and added to the tissue section 
for 4 minutes exactly at 25°C. The tyramide is then removed and another aliquot 
of streptavidin-HRP is added to the slide at the same concentration and 
temperature as described above. Finally, DAB is added to the slide and the 
degree of staining is assessed under a light microscope until the desired signal 
intensity is reached.  
 
5) Counterstaining and Mounting 
In order to contrast the signal generated through IHC and facilitate the 
visualization of the slide, the slides were stained using Hematoxylin (Sigma-
Aldrich). The solution was added for 1 minute at 25°C. After rinsing it off with 
ddH2O, a solution of Tacha Blue (Biocare Medical) was added to the slide for 10 
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seconds. The elevated pH of the solution causes the hematoxylin to turn blue 
within the nuclei of the tissue. After rinsing the slides with ddH2O, they were left 
to air-dry overnight, before being mounted using Permount (Sigma-Aldrich). 
 
Microscope Counting Procedure  
In order to count the microvessel density within pancreatic tumors, slides 
were photographed using a brightfield microscope (Nikon) equipped with a 
camera (Spot Imaging). 20 fields of each slide were photographed and then 
submitted for analysis using a software called ImageJ. Microscope pictures were 
converted to binary prior to being subjected to automatic particle detection by the 
application. Pixel thresholds, determining the size of the particles to be counted, 
were set arbitrarily. However, the same threshold was applied to each image. 
Large necrotic areas in the tissue were avoided due to the absence of countable 
vessels as displayed in Figure 8. The size of a field was also assessed using 




Figure 8: Counting procedure in necrotic tissue areas.  IHC performed on 
mouse pancreatic tumors from the prevention trial. Staining with TUNEL reveals 
vast necrotic areas within the tumor that are poorly vascularized, in contrast to 
the bordering tissue, which is perfused much more adequately, as depicted in 




Measuring Tumor Size in Liver Metastases  
Photographs of entire, H&E stained liver sections were taken using a 
camera equipped with a 65mm macro lens (Canon). The pictures were then 
subjected to ImageJ analysis. The area of the metastases within the livers were 
measured along with the area of the entire livers. The size of the metastases was 
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Western Blot analysis allows for the identification of protein based on size 
and its specificity to the primary antibody. In this project, the technique was used 
in order to identify the presence of SEMA3F in liver and cell lysates. The detailed 
procedure is presented below. 
 
1) Gel Preparation  
Protein was run through a 7.5% SDS PAGE gel. The gel consists of two 
parts, a bottom part called the resolving gel and a top part called the stacking gel. 
The stacking gel allows the proteins to run uniformly to the bottom while the 
resolving gel separates the protein based on size. The stacking gel was prepared 
in a glass chamber (BioRad) using 30% acrylamide/0.8% bis-acrylamide, 1.25 
mL of 0.5M tris-HCl/0.4% SDS at a ph of 6.8 (National Diagnostics) 25uL of 10% 
ammonium persulfate (APS) and 5 uL of tetraethylmethylenediamine (TEMED, 
J.T. Baker Inc.) The resolving gel on the other hand was made using 3.75 of 30% 
acrylamide/0.8% bis-acrylamide (National Diagnostics), 3.75mL of 4x 1.5M tris-
HCl/0.4% SDS at a pH of 8.8 (National Diagnostics), 50uL of 10% APS, 10uL of 
TEMED (J.T. Baker Inc.) and 7.5mL of ddH2O. 
The resolving gel was pour into the chamber first and air dried in order to 
allow it to polymerize. A thin layer of methanol was squirted on top of it in order to 
prevent the formation of bubbles. After 30 minutes, the methanol was removed 
from the top and the stacking gel was added to the chamber. A 15 or 10-well 
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comb was added into the stacking gel in order to induce the formation of wells. 
Following polymerization, the gel was wrapped in a damp paper towel and stored 
at 4°C. 
 
2) Running and Transferring  
The protein samples of interest were diluted in ddH2O and denatured 
using heat and through the addition of an SDS reducing buffer 
(MANUFACTURER). A container filled with 1x running buffer (Boston 
Bioproducts) was used to hold the gels. Equal amounts of protein were loaded 
into each well, except for one well in which 15uL of Precision Plus Dual Protein 
Dual Color Standards (Bio Rad) was loaded. The running procedure was 
conducted at 100V for a duration of 2 hours. The gels were then removed from 
the running apparatus and submerged in 1x transfer buffer (Boston Bioproducts). 
Next, a so-called “sandwich” was assembled consisting of the gel in 
contact with a nitrocellulose membrane (Bio Rad), flanked by two pieces of filter 
paper and two sponges. The sandwiches were loaded into another plastic 
container filled with 1x transfer buffer. A stir bar was put into the container, as 
well as an ice pack, in order to prevent overheating during the transfer 
procedure. Transferring requires a total of 600 milliJoules (mJ). This total can be 
achieved in a multitude of ways and depends on the magnitude of the current 
applied over a certain period of time. Usually, 300mA were provided over a 2-
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hour period to ensure the complete transfer of protein from the gel to the 
membrane.     
 
3) Membrane Blocking, Antibody Incubation and Exposure 
Following transfer, an aliquot of Ponceau (Sigma-Aldrich) solution was 
added to the membrane to make a crude estimate about the presence of protein 
on the blot. The solution was rinsed off by adding ddH2O to the membrane and 
by placing it on a shaker for a duration of 15 minutes. The membranes were then 
blocked in 5% milk diluted in tris-buffered saline (TBS, Bio Rad). Primary 
antibodies were diluted 1:1000 in tris-buffered saline with 1% Tween (TBS-T, 
Boston Bioproducts, Sigma-Aldrich) and incubated on the membranes for at 4°C 
overnight. The following day, the membranes were risned using 3x15 minute 
TBS-T washes. After that, a secondary HRP-linked antibody was added to the 
membrane and incubated at 25°C for 1 hour. After a final 3x15 minute rinse in 
TBS-T, a 1:1 mixture of oxidizing reagent and Enhanced Luminol Reagent 
(Perkin Elmer) were added to the blot and shaken for a 5-minute period. The 
membranes were then analyzed using a Chemidoc Imaging System (Bio Rad). 
 
4) Membrane Stripping 
In the advent of a membrane needing to be reprobed with a different 
antibody, the membranes were subjected to a stripping procedure, meant to 
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remove the previous antibody from the blot. An aliquot of 5 ml of Stripping Buffer 
(Thermo Scientific) was added to the blots for 20 minutes. After removing the 
stripping buffer, the membranes were washed with TBS-T for 45 minutes on a 
shaker. The blots were then blocked with 5% milk prior to the addition of the 




In-vivo experiments for this project involved the syngeneic, orthotopic 
injection of Panc0H7 cells into two main groups of experimental mice. The first 
group were transgenic Nrp2 mice, while the other group consisted of WT 
C57/BL6 mice, which were used for the preclinical trials. The methods for each 
group are detailed below. Mice were housed in an AAALAC accredited animal 
facility at the Boston Children’s Hospital. The steps involved in the orthotopic 





Figure 9: Procedural steps involved in the orthotopic injection of PDAC 
cells in mice. (A) Aseptic surgical field and setup. The mouse is anesthetized 
using a mixture of isoflurane and oxygen. The delivery of anesthetic drug is 
adjusted based on the mouse’s breathing pattern. (B) Dorsal incision at the level 
of the kidney with scissors and forceps. (C) Finished incision allows access into 
the abdominal cavity. (D) Externalization of the spleen (dark red) and the 
pancreas (light pink). (E) injection of cells into the pancreas. The cotton swab 
prevents any leakage of cell out of the organ. (F) The inside layer of the incision 





1) Transgenic Nrp2 -/- mice 
The transgenic mice were purchased from Jackson Laboratories and their 
formal name is Nrp2^tm1.2Mom/MomJ. In order to prevent the expression of 
Nrp2, a portion of exon 1 was removed through genetic recombination using both 
the cre/lox anf the flp/frt systems. The resulting gene product lacked a portion of 
exon 1 as well as the transcription start codon ATG. In order to fully ensure the 
lack of expression, the tau-GFP cassette is followed by a polyadenylated tail, 
which signals the end of transcription in-vivo. The exact gene construct is shown 
in Figure 10. We performed orthotopic and ectopic injections of 1*106 Panc0H7 
cells into WT, Het and KO mice. Given that the Panc0H7 cells originate from a 
mouse, the injection is considered to be syngeneic. The ectopic injections were 
performed subcutaneously with the intention of allowing a more accurate 






Figure 10:  Gene construct in the Nrp2 KO mice. LoxP sites flank the ATG 
start codon in exon 1 as well as a portion of the exon itself and part of the intron 
that follows it. FNF designates a neomycin selection cassette, which is flanked by 
FRT sites and subsequently spliced out in the final product through flp-mediated 
recombination. The only portion of the gene left following recombination with Cre 
is a small fragment of exon 1, followed by the tau-GFP cassette, which itself 
contains a polyadenylated tail. 
 
 
2) Preclinical SEMA3F trials: Prevention 
In order to investigate the role of SEMA3F as a potential therapeutic 
option for the treatment of PDAC we set up three separate trials, all of which 
relied on the use of a SEMA3F expressing adenovirus. The first one is referred to 
as the prevention trial, because the injection of SEMA3F (n=5) and control virus 






3) Preclinical SEMA3F trials: Experimental Prevention 
An experimental metastases procedure refers to the injection of Panc0H7 
cells into the spleen as opposed to the normal orthotopic site, namely the 
pancreas. The goal is to facilitate the non-spontaneous formation of metastases 
to the liver and the model is known to promote the formation of larger and more 
aggressive tumors in the liver. The trial also involves the injection of control (n=3) 
and SEMA3F (n=5) virus 3 days prior to the injection of Panc0H7 cells into the 
spleen. 
 
4) Preclinical trials: Intervention  
This trial was meant to simulate a more realistic clinical scenario in which 
a patient presents to the clinic and requires treatment following the diagnosis of 
PDAC. As a consequence the series of events was inverted for this trial. The 
control (n=4) and SEMA3F (n=5) adenovirus injections were performed three 












NRP2 expression in human PDAC increases with disease progression  
In order to test whether human pancreatic tissue expressed NRP2, 
previous members of our laboratory performed immunohistochemistry (IHC) on a 
human PDAC tissue microarray. NRP2 staining in normal human pancreas 
showed moderate expression in alpha cells within the islets of Langerhans and 
weak expression in large veins and lymphatic vessels. Staining was absent in 
ductal cells and capillaries (Figure 11A). In contrast, human PDAC biopsies 
showed intense NRP2 expression at various stages of the disease, with later 
stages showing increased levels of expression (Figure 11B). Importantly, the 
ductal tumor cells expressed NRP2 in addition to tumor-associated blood 
vessels. PDAC staging is classified based on the size of the tumor (T, ranging 
from 0 to 4), the number and location of lymph nodes containing neoplastic cells 
(N, ranging from 0 to 3) and the presence of distant metastases (M, ranging from 
0 to 1), according to the American Joint Committee on Cancer (AJCC) and the 




Figure 11: NRP2 expression in different types of human pancreata. A: A 
healthy human pancreas stained with a human specific NRP2 antibody reveals 
that the receptor is primarily located within the islets of Langerhans, veins and 
lymphatics, as indicated by the arrows. B: At both T2 and T3, NRP2 expression 
is present on the pancreatic ductal adenocarcinoma cells. The presence of the 
receptor at T3 is greater than at T2 and both stages show an increase in NRP2 
expression compared to the healthy control. NRP2 is also evident in the 







NRP2 expression is upregulated in multiple human PDAC cell lines 
In order to compare the expression of NRP2 in multiple human PDAC cell 
lines, protein lysates were subjected to SDS-PAGE and Western Blot analysis by 
the Bielenberg lab. The results in Figure 12 indicate high levels of expression in 
HPAF-II cells and moderate levels in AsPC-1 and BxPC3. PANC-1 levels were 
lower in comparison. GAPDH served as the loading control for the gel while PAE-
NRP1 served as the negative control and PAE-NRP2 was used as the positive 
control.  
 
Figure 12: Immunoblot analysis of protein lysate from 4 human PDAC cell 
lines. The cell lines, which include HPAF-II, AsPC-1, BxPC-3 and PANC-1, 
showed variable expression of NRP2 (130kD). PAE NRP1 lysate served as a 
negative control while PAE NRP2 lysate served as the positive control for NRP2. 
The blot was stripped and reprobed for GAPDH (37kD) to control for loading. 






Confirming Nrp2 expression in Panc0H7 cells  
Before performing the different experimental trials, we needed to ensure 
that our mouse PDAC cell line Panc0H7 expressed Nrp2. As a consequence, 
previous members of the Bielenberg lab subjected Panc0H7 cells to Western 
Blot analysis and compared it to Nrp2 expressing brain tissue (positive control) 
and Nrp2 deficient brain tissue (negative control), as indicated in Figure 13.  
 
Figure 13: Immunoblot analysis of Panc0H7 indicates the presence of Nrp2. 
Brain tissues either expressing Nrp2 or not were used as positive and negative 
controls respectively. β-actin was used as the loading control. Data from 
Bielenberg et al. 2018.  
 
 Proving that pancreatic tumors that resulted from orthotopic Panc0H7 
injections were positive for Nrp2 was essential for the purpose of this project, 
given that part of this study was aimed at analyzing the potential use of SEMA3F 
as a treatment option for PDAC. Furthermore, it was of essence to prove that the 
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pancreatic cancer cells that metastasized to the liver themselves retained their 
elevated Nrp2 expression levels. As a consequence, IHC was performed on a 
control liver from the experimental prevention trial. Figure 14 shows the 
abundance of Nrp2 expression in the liver metastasis.   
 
Figure 14: Nrp2 expression Panc0H7 metastases in the liver. IHC was 
performed on a control liver from the experimental prevention trial. The brown 










Liver metastases are of pancreatic origin and are mitotically active 
 Considering that no one had previously assessed Panc0H7’s ability to 
metastasize to the liver, livers isolated from the intervention and prevention trials 
were analyzed through immunohistochemistry. The first series of staining was 
aimed at confirming that neoplastic cells had migrated and anchored into the 
liver. KI67, a nuclear proliferation marker was used to differentiate neoplastic 
cells from healthy hepatocytes, considering that these cells rarely divide under 
physiological conditions.  
 Neoplasms however, are mitotically active and tend to divide and proliferate 
rather quickly. As a consequence, KI67-positive nuclei amongst the healthy 
stromal cells of the liver were identified as neoplastic cells, as shown in panel A 
of Figure 15. In order to confirm that the metastases were of pancreatic origin, a 
different section of the same liver was stained for PDX1, a transcription factor 
that is found in the pancreas but not in the liver, as shown in panel B of Figure 
15. The H&E staining in panel C further illustrates the histological and 





Figure 15: Analyzing the presence of metastases in the liver using different 
antibodies. IHC performed on a control liver from the experimental prevention 









Nrp2 facilitates primary tumor growth was well as the formation of 
metastases  
 In an effort to investigate the role of Nrp2 in pancreatic cancer, previous 
members of the Bielenberg lab performed an orthotopic injection of 1 million 
Panc0H7 cells into WT, Het and Nrp2 -/- mice. We hypothesized that the size of 
the primary tumor in the pancreas, as well as the metastases in distant organs, 
would be significantly reduced in Nrp2 -/- and +/-  mice compared to the WT 
control. After allowing the growth of the primary tumor and the formation of 
metastases and ascites in the liver and the peritoneal cavity, multiple organs 
were collected in order to assess any differences in weight.  
 In order to measure the growth of the primary tumor and the presence of 
metastases in distant organs, the mass of three organs was measured, including 
the pancreas, the spleen and the liver, as seen in Figure 16. The weight of both 
the pancreas and the liver in the WT mice was significantly increased compared 
to the KO group (p<0.05) (A). While none of the values were statistically 
significant for the Het mice, the results show a trend that corresponds to the 
expected phenotype, considering that the size of the organs in Het mice was 
increased compared to the WT control and decreased compared to the KO mice. 
None of the values in the spleen were significant, but here again, the results 






Figure 16: Analyzing the growth of the primary tumor and metastases by  
measuring the mass of the pancreas, liver and spleen. (A): The pancreata  
and livers of WT mice are significantly larger than the Nrp2 -/- mice (p<0.05). Het  
mice did not display significant results, but follow a clear phenotypic trend. The  
values collected for the spleen follow the same trend as the ones collected from  
the pancreas and the liver, although the values are not statistically significant.  
(B): Photographs of the pancreata collected from each experimental group.  




Considering Nrp2’s role as mediator of angiogenesis and 
lymphangiogenesis, we hypothesized that the microvessel density within the 
pancreatic tumor would be decreased in the Het and Nrp2 -/- mice. In order to  
test this hypothesis, IHC using an antibody directed against endothelial marker  
CD31 was performed on the tumors. CD31-positive vessels were counted and  
their density was quantified by the area of a 200X microscope field. The results  
shown in Figure 17 indicate a decrease in tumor vascularization in Het tumors  





Figure 16: Analyzing the growth of the primary tumor and metastases by 
measuring the mass of t  pancreas, liver and spleen. (A): The pancreata 
and livers of WT mice are significantly larger than the Nrp2 -/- mice (p<0.05). Het 
mice did not display significant results, but follow a clear phenotypic trend. The 
values collected for the spleen follow the same trend as the ones collected from 
the pancreas and the liver, although the values are not statistically significant. 
(B): Photographs of the pancreata collected from each experimental group. 
Bielenberg et al. unpublished. 
 
 
 Considering Nrp2’s role as mediator of angiogenesis and 
lymphangiogenesis, we hypothesized that the microvessel density within the 
pancreatic tumor would be decreased in the Het and Nrp2 -/- mice. In order to 
test this hypothesis, IHC using an antibo y directed against endothelial marker 
CD31 was performed on the tumors. CD31-positive vessels were counted and 
their density was quantified by the area of a 200X microscope field. The results 
shown in Figure 17 indicate a decrease in tumor vascularization in Het tumors 
compared to WT controls. Nrp2 -/- tumors experienced an even greater decrease 
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in vascularization. Both the difference between WT and Het as well as the 
difference between WT and KO were statistically significant (p<0.05).  
 
 
Figure 17: Microvessel density counted in pancreatic tumors from WT, Het 
and KO mice. The microvessel density of pancreatic tumors was measured by 
counting CD31 positive vessels on a 200X field. The results confirm our 
hypothesis, considering that the vessel density is highest in the WT compared to 
the Het and KO mice. All three differences are statistically significant (p<0.05). 




Investigating the role of SEMA3F in the growth of pancreatic tumors and 
the formation of liver metastases 
 
1) Determining SEMA3F and control adenoviral titer and function in vivo and 
in vitro 
 After investigating the role of Nrp2 on primary tumor and metastases growth, 
our goal was to determine the effect of SEMA3F on pancreatic cancer, given that 
SEMA3F acts as a Nrp2 inhibitor. Our hypothesis was that there would be a 
significant decrease in both the growth of the primary tumor as well as the 
number of liver metastases in the SEMA3F-treated group. Furthermore, knowing 
that SEMA3F acts as an inhibitor of angiogenesis, we predicted that the 
SEMA3F-treated mice would display a reduction in tumor vascularization. In 
order to test our hypotheses, we setup two series of experimental trials, including 
two prevention and one intervention trial.  
 In order to induce the expression of SEMA3F in the liver, the mice from 
every trial were injected with an adenovirus which expressed a His-tagged 
SEMA3F protein. The rationale behind using an adenovirus was that they 
commonly infect the liver, where they induce the expression of high levels of 
protein for a period of about 20 days. Control mice were injected with 
adenoviruses that lacked the SEMA3F coding sequence. The prevention trial 
involved the injection of the virus 3 days prior to the orthotopic implantation of 
Panc0H7 cells. In our “experimental prevention trial” the injection of Panc0H7 
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cells was performed ectopically into the spleen. Injecting cells into the spleen 
facilitates the development of metastases in the liver and simulates a more 
aggressive form of pancreatic cancer.  
 The intervention trial was meant to replicate a more realistic scenario of a 
patient requiring treatment after the development of the early stages of PDAC. As 
a consequence, the virus injection for this trial was performed 3 days after the 
orthotopic injection of Panc0H7 cells. The timeline of these experiments is 
depicted in Figure 18.  
 
 
Figure 18: Timeline of virus injection and Panc0H7 injection in mice. For the 
two prevention experiments, the virus injections were performed three days prior 
to tumor implantation. The sequence of these events was inverted for the 
intervention trial. 
 
 Before starting the prevention and intervention experiments, the function of 
the adenovirus had to be confirmed, in-vitro and in-vivo. The first functionality test 
was done in the form of a “Multiplicity of Infection” assay, which consisted in 
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infecting hTert cells and analyzing protein expression based on time or dose. For 
the dose response, supernatant from infected hTert cells was collected three 
days after the initial infection. The dose of viral particles were multiples of the 
number of cells plated on day 0 and included 1x, 10x and 100x. Western Blot 
analysis of the supernatant indicates that only the highest dose showed a band 
on day 3. Given these observations, the time response was performed by 
infecting the cells at the 100x dose and the supernatant was collected on the 
first, second, third and fourth day after infection. The results depicted in Figure 20 
show that the protein is being expressed in a time-dependent manner. 
 In order to ensure that the adenovirus would express detectable amounts of 
SEMA3F in the mouse liver, C57/BL6 mice were sacrificed at different days 
following an intravenous adenovirus injection. The livers were collected and 
submitted to Western Blot analysis using a Histidine antibody, directed against 
the histidine tag on the viral SEMA3F protein, as depicted in Figure 19. Our 
results indicate the presence of early bands after only 24 hours (A). 12.5 and 
25ng of pure SEMA3F was loaded as a positive control and allows an estimation 
of the amount of SEMA3F present in the liver. The end of expression is also 







A     B 
 
Figure 19: Western Blot analysis of in-vivo SEMA3F expression using an 
antibody directed against the histidine tag on the SEMA3F protein. The first 
five days of SEMA3F expression are depicted in (A) and the last days are shown 
in panel (B). Actin was used as a loading control. 
 
Figure 20: Western Blot analysis of SEMA3F protein expression in hTert 
cells. Both the dose and the time response were analyzed using an antibody 
directed against either the Histidine tag on the SEMA3F protein or the protein 
itself. The His antibody reveals exogenous SEMA3F, while the normal SEMA3F 
antibody indicates the presence of both endogenous and exogenous protein. 
Bielenberg et al. unpublished.  
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 In an effort to quantify the virus, a viral titer was calculated by infecting 
HEK293A cells with different amounts of control and SEMA3F viral stock. IHC 
using an antibody directed against hexon protein was used in order to detect viral 
particles in the infected HEK293A cells. IFU stands for Infectious Units and is the 
result of a calculation, as described in the methods section. The dilution refers to 
how much the purified virus was diluted from its original concentration before 
being added to the HEK293A cells. 
 
Dilution IFU Virus 1 IFU Virus 2 
1.00E-04 3.48E+09 1.84E+09 
1.00E-05 6.89E+09 1.04E+10 
1.00E-06 1.46E+10 3.34E+10 
 
Table 2: Infectious units for 2 separate virus preparations based on dilution 
from stock. Calculated infectious units of 2 separate purified SEMA3F 
adenoviruses relative to the dilution from their original concentration following 
stock expansion and purification. 
 
 
Preclinical SEMA3F Drug Trials  
 
1) Prevention Trial 
 After quantifying viral particles and confirming their activity in-vivo, mice 
received an intravenous injection of either SEMA3F expressing adenovirus (n=5) 
or control adenovirus (n=4). Three days following treatment, the mice received an 
orthotopic injection of 0.5 million Panc0H7 cells. All the mice were sacrificed on 
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day 17 after tumor implantation. Several organs, including the liver, pancreas and 
spleen, were collected in order to conduct a series of experiments including IHC 
and Western Blots.  
 Just like in the Nrp2 transgenic mouse experiment described above, the 
mass of the organs was assessed in order to determine the growth of the primary 
tumor and the liver metastases. Our results in Figure 21 show that the primary 
tumor in the pancreas of control virus-treated mice was significantly increased 
compared to the SEMA3F virus-treated mice (p<0.05). The results in the liver 
were not significant but a similar trend was observed. There was also no 
significant difference in the size of the spleen between the experimental and 
control mice. 
 
Figure 21: Mass of the spleen, pancreas and liver from control and 
experimental mice. The organs were collected on day 17 after tumor 
implantation. Bielenberg et al. unpublished. 
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 The decrease in primary tumor growth was accompanied by a reduction in 
microvessel density. In order to count the density of vessels perfusing the tumor, 
IHC using an antibody directed against CD31 was used. The number of vessels 
per field was counted for 20 fields at 100X magnification.  
 The results are displayed in Figure 22 and show a reduction in microvessel 
density in the pancreatic tumors of the SEMA3F-treated mice (n=4) compared to 




Figure 22: Microvessel density counted in pancreatic tumors from the 
prevention trial. Control tumors (n=4) appear to be more vascularized compared 
to the SEMA3F-treated tumors (n=4). Microvessel density was calculated by 





2) Experimental Prevention Trial 
 An experimental metastases procedure consists in the ectopic injection of 
cancer cells into the spleen in order to facilitate the formation of metastases in 
the liver. Just like in the previous prevention trial the ectopic Panc0H7 injection 
was performed three days after SEMA3F (n=5) and control adenovirus (n=3) 
injection. Mice were sacrificed on day 17 following Panc0H7 implantation and 
their organs were collected for further studies.  
 Just like in the first prevention trial, microvessel density was measured using 
an antibody directed against CD31, an endothelial cell marker. Figure 23 shows 
a control (A) and a SEMA3F (B) stained pancreatic tumor.  
 
 
Figure 23: Example of two separate 200X fields of pancreatic tumors 
stained with CD31 antibody. IHC performed using an antibody directed against 





 CD31-positive cells were counted and the microvessel density is depicted in 
Figure 24. The results indicate a clear statistically significant decrease 
(p<<<0.05) in tumor vessel density in the SEMA3F treated mice (n=3) compared 
to the control (n=2). 
 
 
Figure 24: Microvessel density counted in pancreatic tumors from the 
experimental prevention trial.   IHC performed on pancreatic tumors using an 
antibody directed against CD31 reveals a decrease in microvessel density in the 
SEMA3F-treated group compared to the control. 
 
 Given the particularly aggressive and proliferative character of experimental 
metastases, the gross anatomy of the spleen, the pancreas and the liver in the 
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control mice was so deformed, that the mass of the organs could not be 
assessed accurately. As a consequence, instead of measuring the weights of the 
organs, the growth of metastases in the liver was analyzed under light 
microscopy. H&E stained livers display the presence of tumors in the liver 
accurately on their own, but nonetheless, the liver slides were stained with an 
antibody directed against PDX-1 in order to confirm the identity of pancreatic 
metastases. Figure 25 shows a control treated liver (A) and a SEMA3F treated 
liver (B). The pancreatic metastases in the liver can be seem most clearly in (A), 






Figure 25: Examples of Control and SEMA3F-treated livers from the 
experimental prevention trial. H&E stained control (A) and SEMA3F (B) treated 




 In order to quantify these results, the areas of the metastases and of the 
entire liver lobe were calculated in order to determine the percentage of healthy 
tissue that has been replaced by Panc0H7 cells. The results are shown in Figure 
26. The SEMA3F livers had a significantly higher percentage of their area 
comprising of pancreatic metastases compared to the control (p<0.05). 
 
 
Figure 26: Percentage of liver area covered in metastatic tissue from the 
experimental prevention trial. Percentage of liver lobes in both the control 




3) Intervention Trial 
 The intervention trial was meant to simulate a more realistic scenario in 
which a patient presents to a clinic in order to receive treatment following the 
diagnosis of PDAC. As a consequence, the mice received an orthotopic injection 
of 1 million cells/µl 3 days prior to an injection of either control (n=4) of SEMA3F-
expressing (n=5) adenovirus. The mice were sacrificed slightly earlier than in the 
two prevention trials, namely day 14 post tumor inoculation. Again, the relevant 
organs including the liver and the pancreas were collected. There was no 
significant difference in the weight of the organs for this trial, as depicted in 
Figure 27. 
 
Figure 27: Weights of the pancreas, the liver and the spleen from the 
intervention trial. There was no significant difference between the control 
treated organs compared to the SEMA3F treated organs. Data from Bielenberg 




 As described above, the microvessel density was calculated using CD31 
staining on the pancreatic tumors. The results depicted in Figure 28 indicate a 
statistically significant decrease in vessel density (p<<0.05) in the SEMA3F 
adenovirus-treated mice (n=4) compared to the control virus (n=2) treated mice.  
 
 
Figure 28: Microvessel density measured in pancreatic tumor from the 
intervention trial. IHC performed on pancreatic tumors using an antibody 
directed against CD31 reveals a decrease in microvessel density in the 








 PDAC is a particularly aggressive disease and it has stood out from other 
forms of cancer due to its high mortality rate and the lack of treatment currently 
available to combat it. Current treatment options are limited to non-specific 
chemotherapeutic drugs like gemcitabine or surgical resection, neither of which 
has proven to prolong survival rates in a significant way. As a consequence, 
there is a dire need to investigate the use of novel therapeutic approaches. In 
this thesis project, we show evidence that SEMA3F could be used to develop a 
novel therapeutic approach against PDAC. The experimental rationale and the 
discussion of the results is presented below.  
 
Experimental Rationale 
1) Nrp2 transgenic mouse model 
The reason behind targeting Nrp2 as a potential new drug for the 
treatment of PDAC was based on a number of observations. First and foremost, 
in humans, it has been shown that NRP2 expression is elevated in PDAC, both 
on the vasculature and the PDAC cells themselves, and the degree of expression 
is positively correlated with disease progression. Furthermore, based on the work 
of Caunt et al. (ref) and Dallas et al (ref)., it is known that by targeting Nrp2 either 
through a neutralizing antibody or by silencing its expression using small 
interfering RNA, there is a decrease in primary tumor growth and in the formation 
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of metastases. As a consequence, this project was aimed at further explaining 
the implication of NRP2 in PDAC using a transgenic mouse model, as well as 
targeting the receptor with its endogenous inhibitor, SEMA3F in order to explore 
a potential therapeutic solution for the disease.  
Our PDAC model involved the orthotopic injection of syngeneic PDAC 
cells in C57/BL6 mice. Other models usually rely on the use of Cre/Lox mice in 
which the expression of a mutated Kras is driven by a pancreas-specific 
promoter, or they are based on immunodeficient mice in which human cells are 
injected. Syngeneic orthotopic injections lead to the rapid development of an 
aggressive form of PDAC, unlike Cre/Lox driven models. Furthermore, they are 
performed in mice that maintain a perfectly functional immune system, which is a 
major actor in cancer. By using Nrp2 -/- mice, we were able to ensure the 
complete absence of the receptor in our model, something that cannot be 
achieved by using a neutralizing antibody or short interfering RNA. The novelty of 
our experimental designs also lies in the fact that we are the first to perform a 
syngeneic, orthotopic injection of PDAC in Nrp2 -/- mice, which have so far 








2) SEMA3F virus trials 
Thoughtful preparation also went into the establishment of our SEMA3F 
trials. Using an adenovirus to induce the expression of SEMA3F for example, 
offers a number of advantages that are not possible in other models. Another 
alternative would have been to perform daily intravenous injections of SEMA3F 
protein into our mice. While injecting the protein would have been a more realistic 
representation of the use of SEMA3F as a drug, it would also have been very 
costly and time consuming. On top of that, neither the pharmacokinetics nor the 
pharmacodynamics of the protein are known and consequently, injecting it would 
have been unreliable and devoid of any scientific rationale. Besides the practical 
and financial attributes of an adenovirus are that it is also particularly useful for 
inducing the expression of SEMA3F in the liver, considering that adenoviruses 
have a tendency to infect that organ in particular.  
Furthermore, following infection, it maintains high levels of protein 
expression for a period of time that overlaps almost entirely with our disease 
model. Our data showed that the protein was still present in the liver at 
detectable levels as late as 15 days following injection. Given the aggressive 
proliferative nature of PDAC, the virus-induced expression of SEMA3F coincides 
almost perfectly with the progression of the disease in the mice, which tend to 
succumb to the symptoms of PDAC about 20 days after tumor implantation. In a 
way, the absence of the protein after 15 days renders our results even more 
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significant then they would have been if the expression of SEMA3F had persisted 
until we sacrificed the mice.  
 
Nrp2 -/- mouse experiments - Results 
Before summarizing the experiments that were performed in Nrp2 -/- mice, 
it is important to remember which cells within our mouse model expressed Nrp2 
and which didn’t. While the receptor was not being expressed in our total KO 
model, it is critical to recall that Nrp2 is still expressed on the Panc0H7 cells that 
were injected into our mice. As a consequence, the observed decrease in 
primary tumor growth and metastases is primarily due to the absence of the 
receptor on endothelial cells. In other words, the lack of Nrp2 in our KO mice 
reduced tumor growth by limiting the proliferation of the vasculature. This is 
supported by our observation that the tumor microvessel density was reduced in 
the WT mice compared to the Het and KO mice.  
Limiting the proliferation of the vasculature during the development of 
cancer is the very basis behind the concept of anti-angiogenic therapies. Tumor-
driven angiogenesis is unregulated and leads to the the formation of tortuous and 
leaky vessels, which are often the cause of ischemia and other vascular-related 
problems. The fact that this type of pathological angiogenesis was reduced in our 
Nrp2 -/- mice also explains the reduced incidence of metastases in the liver.   
However, since Nrp2 is not only expressed on the vasculature, but also on 
certain immune cells and other mediators of the tumor-microenvironment, we 
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cannot conclude with certainty whether or not the absence of Nrp2 on the 
vasculature is the only factor influencing tumor growth in our Nrp2 -/- model. In 
order to eliminate other variables, we would need to use a transgenic model in 
which the lack of expression of Nrp2 would be limited to the vasculature. Cre/Lox 
mice offer a solution to this problem. By driving the expression of Cre using an 
endothelial-specific promoter like VE-cadherin and by floxing the Nrp2 gene, we 
could ensure the knocking-out of the receptor in endothelial cells only. This would 
allow us to narrow down the results of our experiments to angiogenesis-related 
phenomena.  
 
SEMA3F-Virus Trials  
Having shown the anti-angiogenic effects of knocking out Nrp2 in our 
transgenic mouse model, we proceeded to focus our attention on the use of 
SEMA3F, an endogenous inhibitor of Nrp2. The effects of SEMA3F binding to 
Nrp2 can be summarized into three separate effects: anti-angiogenesis, anti-
proliferation and repulsion. These three effects will be discussed in the context of 
the results presented in this manuscript.  
 
1) Anti-angiogenic effects of SEMA3F  
The results from our SEMA3F adenovirus trials indicated a decrease in 
microvessel density, which is unsurprising considering that the protein acts as an 
endogenous inhibitor of angiogenesis and lymphangiogenesis. Similar to the 
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logic behind our transgenic mouse experiments, the antiangiogenic effects of 
inhibiting Nrp2 through an endogenous ligand are likely to be one of the effects 
that limits tumor growth but also its propagation to distant organs like the liver. As 
mentioned above, the disorganized growth of structurally unsound blood vessels 
in a tumor leads to the formation of leaky veins and arteries that might facilitate 
the propagation of metastatic cells into the blood stream.  
Out of all three SEMA3F trials, the only set of pancreatic tumors that did 
not indicate a statistically significant reduction in microvessel density were the 
ones from the prevention trial. Although it is tempting to conclude that SEMA3F 
did not have an effect on the proliferation of the vasculature in these tumors, it 
would be wrong to derive this interpretation. In fact, there was a significant 
reduction in the size of the pancreas in the SEMA3F-virus treated mice 
compared to the control-virus treated mice. It is known that anti-angiogenic 
effects can occur while maintaining the tumor vessel density (Folkman et al. 
2002). In other words, the anti-angiogenic effects of a molecule that causes no 
significant reduction in microvessel density only makes sense if one takes into 
account the reduction in growth of the affected organ.  
But in contrast to our transgenic mouse experiments, we can add another 
level of interpretation to the SEMA3F trials. Based on the theory of vessel 
normalization, a concept discovered by Dr. Rakesh Jain, low levels of anti-
angiogenic therapy improve certain structural features of tumor-promoted 
angiogenesis. One could make the argument that the levels of SEMA3F 
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generated by the adenovirus over a period of 15 days, have an anti-angiogenic 
effect at first, but as the expression levels drop, SEMA3F acts more like a 
normalizing force on the vasculature. The improved structure of the vasculature 
perfusing the tumor would then account for the reduced incidence of metastases 
observed in our experimental mice compared to our control.  
Furthermore, the normalizing effects of SEMA3F can be observed through 
TUNEL staining, an IHC procedure that detects the presence of damaged DNA in 
a tissue and therefore exposes areas of necrotic or apoptotic tissue. Based on 
preliminary observations, it seems as if the control tumors display larger areas of 
necrotic tissue compared to the SEMA3F treated mice, as shown in Figure 29. 
This observation could be either due to the fact that PDAC growth in control mice 
is so rapid that the vasculature does not have enough time to proliferate and 
adequately perfuse the tissue, leading to areas of necrosis and apoptosis. The 
other possibility is that the stabilizing effects of SEMA3F on blood vessels 
prevent the formation of areas in the tumor that do not receive adequate blood 





Figure 29: Zone of necrotic tissue within a control tumor. The staining was 
performed using TUNEL on a control pancreatic tumor from the experimental 
prevention trial. The pink staining in the middle of the tumor reveals a large area 
of necrotic tissue which arose either due to rapid tumor growth or inadequate 




2) Anti-proliferative effects of SEMA3F 
 
The anti-proliferative actions of SEMA3F were not included in the results due 
insufficient data and analysis, but there are preliminary results that an be 
addressed in this discussion. The proliferative behavior of pancreatic tumor cells 
was measured using KI67 staining. Expression of KI67 in a cell is indicative of its 
proliferative behavior. Livers were stained with an antibody directed against this 
molecule in order to reveal the presence of metastases, whereas pancreatic 
tumors themselves were stained with the same antibody in order to indicate how 
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mitotically active the cells were in the different trials. Rough data indicate that 
SEMA3F-treated mice show lower levels of proliferation within their pancreatic 
tumors compared to the control, as indicated by Figure 30. 
 
 
Figure 30: IHC performed in pancreatic tumors from the experimental  
prevention trial using an antibody directed against KI67. Brown, positive  
nuclei indicate the expression of Ki67 within that cell. (A) Representative  
photograph of a 100X field of a control pancreatic tumor stained with Ki67.  (B) 
Representative photograph of a 100X field of a SEMA3F-treated pancreatic  
tumor stained with Ki67. A rough evaluation of preliminary data indicates a  
difference in the proliferative character of pancreatic cancer cells in the control  




In order to further confirm the anti-proliferative character of SEMA3F, we 
would need to conduct further experiments such as a proliferation assay which 
consists in evaluating the proliferative behavior of Panc0H7 cells in-vitro. The 
assay consists in exposing different concentrations of cells to various amounts of  
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mitotically active the cells were in the different trials. Rough data indicates that 
SEMA3F-treated mice show lower levels of proliferation within their pancreatic 
tumors compared to the control, as indicated by Figure 30.
 
 
Figure 30: IHC performed in pancreatic tumors from the experimental 
prevention trial using an antibody directed against KI67. Brown, positive 
nuclei indicate the expression of Ki67 within that cell. (A) Representative 
photograph of a 100X field of a control pancreatic tumor stained with Ki67. (B) 
Representative photograph of a 100X field of a SEMA3F-treated pancreatic 
tumor stained with Ki67. A rough evaluation of preliminary data indicates a 
difference in the proliferative character of pancreatic cancer cells in the control 
compared to the SEMA3F treated group. 
 
In order to further confirm the anti-proliferative character of SEMA3F, we 
would need to conduct further experiments such as a proliferation assay which 
consists in evaluating the proliferative behavior of Panc0H7 cells in-vitro. The 
assay consists in exposing different concentrations of cells to various amounts of 
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SEMA3F and then determine whether there is a noticeable change in cell 
proliferation. 
 
3) SEMA3F-induced repulsion 
As discussed in the introduction, the migration of cells involved in the 
formation of the nervous system during development require the use of guidance 
molecules, many of which also play a role in vasculogenesis and-angiogenesis. 
The SEMA3F-NRP2 interaction for example, is necessary to guide the formation 
of neurons between the somites of an embryo. The same receptor-ligand pair is 
thought to lead the development of the vasculature based on a specific molecular 
gradient. Bielenberg et al. have shown that SEMA3F-transfected cells are 
capable of repelling endothelial cells away (Bielenberg et al. 2004c). Figure 31 
shows the zone of clearance established by the presence of SEMA3F-expressing 
cells in the middle of NRP2-positive cells.  
We have shown that Panc0H7 express Nrp2, both through immunoblot 
analysis and IHC performed on liver metastases. As a consequence, it would be 
reasonable to assume that adenovirus-induced expression of SEMA3F in the 
liver is capable of repelling metastatic Panc0H7 away from the liver. However, 
one might argue that repelling the cancerous cells away from the liver will cause 
them to metastasize to a different organ, thereby negating the therapeutic effects 
of SEMA3F-induced repulsion.  
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 This observation certainly constitutes a valid criticism against the use of 
SEMA3F as a treatment for PDAC, but it fails to take into consideration two very 
important points. First and foremost, in our experiments, SEMA3F-expressing 
adenovirus was injected systemically into the bloodstream. As a consequence, 
the expression of the virus is not limited to the liver and is likely to be found in 
virtually any organ of the body. This means that metastatic Panc0H7 cells that 
get repelled from the liver would not simply be able to migrate to any other organ, 
given that other tissues are likely to be infected with the virus and will also repel 
them.  
 
Figure 31: SEMA3F expression creates a zone of clearance within Nrp2-
positive cells. (A) Experimental setup showing the presence of 3 groups of cells 
plated on a microscope slide. SEMA3F-transfected cells lift off and settle down 




Another very common metastatic site for neoplastic cells is the lungs, 
which is one of the areas Panc0H7 cells could migrate to if they were to be 
repelled from the liver. However, in our experiments, injections of adenovirus 
were performed in the mice’s tail vein. Blood from the tail vein is known to drain 
almost immediately to the lungs. Furthermore, the fact that there is an 
abundance of epithelial tissue in the lungs, practically guarantees the infection of 
these organs with the virus.  
Another consideration to take into account is the fact that metastatic cells 
do not seed in random organs. Based on the “seed and soil” hypothesis, it is 
known that certain types of cancer have a tendency to metastasize to very 
specific organs in the body. As a consequence, it would be very unlikely that a 
metastatic Panc0H7 cell that was programmed to seed in the liver, would 
suddenly migrate and proliferate in a completely different type of tissue.  
The ability for SEMA3F to induce repulsion in Panc0H7 cells needs to be 
further tested through a series of in-vitro experiment. The assay would consist in 
plating Panc0H7 cells in a dish containing a point source of SEMA3F protein. 
The point source would be most likely hTerT cells that were infected with 
SEMA3F-expressing adenovirus. Both cell populations would be plated in small 
circles on a microscope slide. After a certain number of days, the cells would be 
fixed, stained and analyzed through IHC in order to assess the ability of the 






The focus of this thesis project was to identify a novel therapeutic 
approach against the growth and propagation of pancreatic cancer, a disease 
that currently lacks effective treatment options. Previous publications, including 
work done in the Bielenberg lab, revealed that NRP2 plays a role in the formation 
and metastasis of PDAC. NRP2 is known as a guidance molecule and for its 
ability to mediate angiogenesis. Furthermore, its expression is elevated in a 
number of different human cells lines, including Panc0H7, the mouse PDAC cell 
line used in this project.  
Our first set of experiments involved the use of a NRP2 -/- transgenic 
mouse model, in which we performed an orthotopic injection of NRP2-expressing 
Panc0H7 cells. Mice that did not express the receptor showed a decrease in 
primary tumor growth and metastasis. We concluded that the results must be due 
to a decrease in angiogenesis in the NRP2 -/- mice, considering that the receptor 
is a potent mediator of angiogenesis. These results encouraged us to investigate 
the use of endogenous inhibitors of NRP2 as potential candidates for anti-
angiogenic drug development.  
We focused our attention on SEMA3F, a secreted protein that acts as a 
competitive inhibitor of a potent pro-angiogenic molecule called VEGF. Our 
SEMA3F experiments showed that this protein could be used for its anti-
angiogenic and anti-proliferative effects in the fight against PDAC. Given 
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SEMA3F’s role as a guidance molecule, it would be very interesting to test its 
ability to repel PDAC cells from common metastatic sites like the liver and the 
lung. However, these experiments remain to be conducted and constitute one of 
the major future directions of this project.  
In summary, we show that NRP2-mediated angiogenesis leads to primary 
tumor growth and metastasis. Furthermore, our results indicate that SEMA3F has 
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